Azoxymethane - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	Azoxymethane	go back to main search page
Accession:	CHEBI:232612	browse the term
Definition:	A potent carcinogen and neurotoxic compound. It is particularly effective in inducing colon carcinomas. (PubChem)
Synonyms:	related_synonym:	Formula=C2H6N2O; InChI=1S/C2H6N2O/c1-3-4(2)5/h1-2H3/b4-3-; InChIKey=DGAKHGXRMXWHBX-ARJAWSKDSA-N; SMILES=C/N=[N+](/C)\\[O-]
	xref:	CAS:25843-45-2
	xref_mesh:	MESH:D001397

show annotations for term's descendants Sort by:
Rat (1069 ) Mouse (1290 ) Human (1077 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (0 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (1069)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

4-aminobutyrate aminotransferase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABAT mRNA

NCBI chr10:7,503,351...7,599,474
Ensembl chr10:7,492,022...7,599,474

G

ATP binding cassette subfamily A member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCA1 mRNA

NCBI chr 5:72,473,676...72,596,563
Ensembl chr 5:72,473,676...72,596,473

G

ATP binding cassette subfamily B member 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1A mRNA

NCBI chr 4:26,312,403...26,488,456
Ensembl chr 4:26,312,409...26,397,135

G

ATP-binding cassette, sub-family B member 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB1B mRNA

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:26,106,903...26,279,567

G

ATP binding cassette subfamily B member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB4 mRNA

NCBI chr 4:26,106,895...26,164,440

G

ATP binding cassette subfamily B member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:84,117,220...84,125,526

G

ATP binding cassette subfamily C member 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC10 mRNA

NCBI chr 9:22,154,811...22,174,743
Ensembl chr 9:22,154,804...22,174,743

G

ATP binding cassette subfamily C member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC3 mRNA

NCBI chr10:79,793,571...79,839,528
Ensembl chr10:79,793,583...79,839,494

G

ATP binding cassette subfamily C member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC4 mRNA

NCBI chr15:101,948,387...102,182,912
Ensembl chr15:101,949,433...102,181,375

G

ATP binding cassette subfamily C member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC5 mRNA

NCBI chr11:93,975,579...94,071,659
Ensembl chr11:93,978,274...94,071,655

G

ATP binding cassette subfamily C member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCC6 mRNA

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895

G

ATP binding cassette subfamily C member 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCC9 mRNA

NCBI chr 4:175,531,854...175,655,849
Ensembl chr 4:177,262,848...177,386,348

G

ATP binding cassette subfamily G member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ABCG1 mRNA

NCBI chr20:9,128,056...9,184,312
Ensembl chr20:9,127,803...9,186,563

G

ATP binding cassette subfamily G member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ABCG2 mRNA

NCBI chr 4:89,006,056...89,132,915
Ensembl chr 4:89,005,969...89,132,493

G

acetyl-CoA acyltransferase 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1A mRNA

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:127,956,129...127,966,241

G

acetyl-Coenzyme A acyltransferase 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:127,750,743...127,759,569

G

acetyl-CoA acyltransferase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACAA2 mRNA

NCBI chr18:70,620,310...70,648,417
Ensembl chr18:70,620,110...70,648,420

G

acyl-CoA dehydrogenase short chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADS mRNA

NCBI chr12:41,493,650...41,502,897
Ensembl chr12:47,154,276...47,164,103

G

acyl-CoA dehydrogenase, short/branched chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACADSB mRNA

NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:195,619,038...195,660,561

G

angiotensin I converting enzyme

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACE mRNA

NCBI chr10:91,410,129...91,430,246
Ensembl chr10:91,409,819...91,430,942

G

acetylcholinesterase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACHE mRNA

NCBI chr12:25,042,882...25,050,608
Ensembl chr12:25,043,461...25,050,410

G

atypical chemokine receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR1 mRNA

NCBI chr13:85,782,396...85,784,015
Ensembl chr13:88,293,188...88,317,807

G

atypical chemokine receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR2 mRNA

NCBI chr 8:121,559,563...121,573,633
Ensembl chr 8:130,384,559...130,464,393

G

atypical chemokine receptor 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:98,246,605...98,260,214

G

atypical chemokine receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACKR4 mRNA

NCBI chr 8:104,716,537...104,720,972
Ensembl chr 8:113,595,293...113,602,372

G

acyl-CoA synthetase bubblegum family member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSBG2 mRNA

NCBI chr 9:1,683,846...1,715,517
Ensembl chr 9:1,770,972...1,801,655

G

acyl-CoA synthetase medium-chain family member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACSM1 mRNA

NCBI chr 1:173,985,715...174,020,565
Ensembl chr 1:183,416,009...183,454,217

G

acyl-CoA synthetase short-chain family member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS1 mRNA

NCBI chr 3:159,910,809...159,960,748
Ensembl chr 3:159,910,809...159,960,748

G

acyl-CoA synthetase short-chain family member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ACSS2 mRNA

NCBI chr 3:164,464,124...164,507,607
Ensembl chr 3:164,464,055...164,519,830

G

actinin, alpha 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN1 mRNA

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:104,731,485...104,826,172

G

actinin alpha 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACTN2 mRNA

NCBI chr17:62,835,055...62,902,331
Ensembl chr17:62,812,988...62,903,552

G

activin A receptor type 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ACVR1 mRNA

NCBI chr 3:42,978,558...43,097,892
Ensembl chr 3:63,387,381...63,477,884

G

ADAM metallopeptidase with thrombospondin type 1 motif, 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS1 mRNA

NCBI chr11:24,932,227...24,941,068
Ensembl chr11:38,418,101...38,427,390

G

ADAM metallopeptidase with thrombospondin type 1 motif, 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS14 mRNA

NCBI chr20:29,143,029...29,219,846
Ensembl chr20:29,685,876...29,762,682

G

ADAM metallopeptidase with thrombospondin type 1 motif, 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS2 mRNA

NCBI chr10:34,920,992...35,126,465
Ensembl chr10:35,422,030...35,627,483

G

ADAM metallopeptidase with thrombospondin type 1 motif, 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS4 mRNA

NCBI chr13:83,670,556...83,680,045
Ensembl chr13:86,202,642...86,212,514

G

ADAM metallopeptidase with thrombospondin type 1 motif, 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADAMTS5 mRNA

NCBI chr11:25,000,627...25,047,205
Ensembl chr11:38,486,955...38,533,516

G

adenylate cyclase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY2 mRNA

NCBI chr 1:36,204,054...36,650,645
Ensembl chr 1:36,204,054...36,650,645

G

adenylate cyclase 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY4 mRNA

NCBI chr15:33,236,201...33,252,070
Ensembl chr15:33,236,208...33,252,026

G

adenylate cyclase 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCY6 mRNA

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:131,621,860...131,642,770

G

adenylate cyclase 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCY7 mRNA

NCBI chr19:18,740,875...18,798,924
Ensembl chr19:34,914,322...34,936,743

G

adenylate cyclase activating polypeptide 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADCYAP1 mRNA

NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383

G

ADCYAP receptor type I

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADCYAP1R1 mRNA

NCBI chr 4:84,593,558...84,642,700
Ensembl chr 4:85,924,100...85,972,973

G

adhesion G protein-coupled receptor A2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRA2 mRNA

NCBI chr16:64,932,964...64,971,433
Ensembl chr16:71,636,164...71,674,154

G

adhesion G protein-coupled receptor B1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADGRB1 mRNA

NCBI chr 7:108,293,681...108,365,892
Ensembl chr 7:108,293,818...108,365,870

G

adhesion G protein-coupled receptor E5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRE5 mRNA

NCBI chr19:24,397,972...24,418,648
Ensembl chr19:41,303,213...41,324,641

G

adhesion G protein-coupled receptor F1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF1 mRNA

NCBI chr 9:17,661,258...17,696,359
Ensembl chr 9:25,147,588...25,208,916

G

adhesion G protein-coupled receptor F5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADGRF5 mRNA

NCBI chr 9:17,517,596...17,624,107
Ensembl chr 9:25,018,277...25,121,237

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADH1 mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:229,470,703...229,482,291

G

alcohol dehydrogenase 5 (class III), chi polypeptide

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADH5 mRNA

NCBI chr 2:226,975,184...226,987,591
Ensembl chr 2:229,648,501...229,665,232

G

adrenomedullin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADM mRNA

NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:174,178,773...174,182,371

G

adenosine A2a receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,270...13,332,802

G

adenosine A2B receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ADORA2B mRNA

NCBI chr10:46,940,394...46,956,772
Ensembl chr10:47,439,701...47,456,091

G

adenosine A3 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADORA3 mRNA

NCBI chr 2:196,077,042...196,080,686
Ensembl chr 2:196,077,042...196,080,686

G

adrenoceptor alpha 2A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ADRA2A mRNA

NCBI chr 1:263,066,780...263,069,580
Ensembl chr 1:263,065,278...263,069,871

G

adrenoceptor beta 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ADRB2 mRNA

NCBI chr18:57,912,760...57,914,802
Ensembl chr18:57,911,348...57,914,803

G

advanced glycosylation end product-specific receptor

multiple interactions
increases expression

EXP

AGER protein results in increased susceptibility to [Azoxymethane co-treated with Glucose co-treated with Linoleic Acid]; Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]; Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]; Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Metformin inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]

NCBI chr20:4,152,758...4,155,956
Ensembl chr20:4,151,965...4,155,685

G

angiotensinogen

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AGT mRNA

NCBI chr19:69,426,540...69,447,017
Ensembl chr19:69,421,638...69,446,944

G

A-kinase anchoring protein 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP12 mRNA

NCBI chr 1:40,730,123...40,819,863
Ensembl chr 1:43,199,008...43,225,557

G

A-kinase anchoring protein 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKAP5 mRNA

NCBI chr 6:100,787,169...100,796,712
Ensembl chr 6:100,790,148...100,796,620

G

aldo-keto reductase family 1 member B1

multiple interactions
increases expression

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AKR1B1 mRNA; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of AKR1B1 mRNA]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of AKR1B1 protein]; Resveratrol inhibits the reaction [Azoxymethane results in increased expression of AKR1B1 mRNA]; Resveratrol inhibits the reaction [Azoxymethane results in increased expression of AKR1B1 protein]
Azoxymethane results in increased expression of AKR1B1 mRNA; Azoxymethane results in increased expression of AKR1B1 protein

PMID:21355597 PMID:29950665

NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:63,899,222...63,913,315

G

aldo-keto reductase family 1, member C3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AKR1C18 mRNA

NCBI chr17:71,020,884...71,037,779
Ensembl chr17:70,970,900...71,048,438

G

AKT serine/threonine kinase 1

multiple interactions

EXP

[Plant Extracts co-treated with Azoxymethane] results in decreased expression of AKT1 mRNA; [Plant Extracts co-treated with Azoxymethane] results in decreased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

albumin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALB mRNA

NCBI chr14:17,891,564...17,907,043
Ensembl chr14:17,891,582...17,911,865

G

aldehyde dehydrogenase 1 family, member A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1A1 mRNA

NCBI chr 1:227,426,939...227,579,497
Ensembl chr 1:227,427,070...227,579,500

G

aldehyde dehydrogenase 1 family, member B1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH1B1 mRNA

NCBI chr 5:64,859,000...64,864,008
Ensembl chr 5:64,858,934...64,864,365

G

aldehyde dehydrogenase 2 family member

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH2 mRNA

NCBI chr12:40,610,244...40,643,220
Ensembl chr12:40,610,224...40,643,219

G

aldehyde dehydrogenase 3 family, member A2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ALDH3A2 mRNA

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:46,407,993...46,448,648

G

arachidonate 12-lipoxygenase, 12R type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX12B mRNA

NCBI chr10:53,863,060...53,874,938
Ensembl chr10:54,361,898...54,373,776

G

arachidonate 5-lipoxygenase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5 mRNA

NCBI chr 4:151,203,948...151,251,126
Ensembl chr 4:151,203,949...151,251,126

G

arachidonate 5-lipoxygenase activating protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALOX5AP mRNA

NCBI chr12:5,748,941...5,772,986
Ensembl chr12:10,785,257...10,817,038

G

alkaline phosphatase, biomineralization associated

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ALPL mRNA

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:155,234,775...155,254,167

G

angiopoietin 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANGPT4 mRNA

NCBI chr 3:140,420,389...140,454,213
Ensembl chr 3:160,880,728...160,913,921

G

anoctamin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO1 mRNA

NCBI chr 1:209,180,755...209,329,413
Ensembl chr 1:209,180,755...209,329,550

G

anoctamin 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO10 mRNA

NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:130,718,755...130,877,636

G

anoctamin 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANO6 mRNA

NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:128,813,068...128,992,799

G

anoctamin 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO7 mRNA

NCBI chr 9:93,917,524...93,945,323
Ensembl chr 9:101,364,842...101,394,173

G

anoctamin 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANO9 mRNA

NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:205,638,572...205,659,489

G

annexin A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ANXA1 mRNA

NCBI chr 1:227,287,713...227,306,739
Ensembl chr 1:227,287,717...227,306,831

G

annexin A4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:120,741,750...120,798,513

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AP1M1 mRNA

NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,616,187...17,636,462

G

APC regulator of WNT signaling pathway

multiple interactions
decreases expression

EXP

Etodolac inhibits the reaction [Azoxymethane results in decreased expression of APC mRNA]; Sulindac inhibits the reaction [Azoxymethane results in decreased expression of APC mRNA]

PMID:11076880 PMID:12458338

NCBI chr18:26,138,382...26,196,021
Ensembl chr18:26,102,679...26,197,022

G

apelin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APLN mRNA

NCBI chr X:132,058,739...132,091,518
Ensembl chr X:132,081,759...132,091,246

G

apolipoprotein B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of APOB mRNA

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:36,563,704...36,611,814

G

amyloid beta precursor protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of APP mRNA

NCBI chr11:37,506,207...37,724,351
Ensembl chr11:37,506,408...37,722,971

G

aquaporin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP1 mRNA

NCBI chr 4:85,812,784...85,824,964
Ensembl chr 4:85,812,784...85,830,504

G

aquaporin 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP11 mRNA

NCBI chr 1:152,046,515...152,056,675
Ensembl chr 1:161,457,754...161,467,945

G

aquaporin 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP2 mRNA

NCBI chr 7:132,590,286...132,595,321
Ensembl chr 7:132,590,225...132,595,319

G

aquaporin 3 (Gill blood group)

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP3 mRNA

NCBI chr 5:61,035,165...61,040,683
Ensembl chr 5:61,035,166...61,040,685

G

aquaporin 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AQP8 mRNA

NCBI chr 1:187,424,314...187,430,243
Ensembl chr 1:187,424,417...187,430,242

G

aquaporin 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AQP9 mRNA

NCBI chr 8:80,678,027...80,718,273
Ensembl chr 8:80,678,030...80,717,240

G

androgen receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AR mRNA

NCBI chr X:67,135,317...67,304,476
Ensembl chr X:67,135,317...67,304,467

G

arginase 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARG1 protein]

NCBI chr 1:22,295,093...22,307,720
Ensembl chr 1:22,295,322...22,307,713

G

Rho GTPase activating protein 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP15 mRNA

NCBI chr 3:27,989,368...28,592,722
Ensembl chr 3:48,382,904...49,011,378

G

Rho GTPase activating protein 20

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP20 mRNA

NCBI chr 8:52,074,472...52,155,739
Ensembl chr 8:60,970,475...61,055,198

G

Rho GTPase activating protein 25

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGAP25 mRNA

NCBI chr 4:119,896,844...119,974,982
Ensembl chr 4:121,454,151...121,552,913

G

Rho GTPase activating protein 40

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGAP40 mRNA

NCBI chr 3:167,585,665...167,626,433
Ensembl chr 3:167,585,665...167,626,532

G

Rho GDP dissociation inhibitor beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGDIB mRNA

NCBI chr 4:169,822,951...169,841,884
Ensembl chr 4:171,554,140...171,573,068

G

Rho guanine nucleotide exchange factor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF1 mRNA

NCBI chr 1:80,499,026...80,520,954
Ensembl chr 1:89,628,266...89,649,067

G

Rho guanine nucleotide exchange factor 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ARHGEF12 mRNA

NCBI chr 8:43,350,070...43,475,404
Ensembl chr 8:52,247,047...52,372,376

G

Rac/Cdc42 guanine nucleotide exchange factor 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ARHGEF6 mRNA

NCBI chr X:135,145,447...135,264,636
Ensembl chr X:140,182,734...140,344,458

G

ankyrin repeat and SOCS box-containing 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ASB2 mRNA

NCBI chr 6:122,474,754...122,511,014
Ensembl chr 6:128,239,552...128,266,321

G

acid sensing ion channel subunit family member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ASIC4 mRNA

NCBI chr 9:76,941,532...76,962,900
Ensembl chr 9:84,390,104...84,411,538

G

ATPase phospholipid transporting 10A (putative)

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP10A mRNA

NCBI chr 1:109,556,760...109,730,440
Ensembl chr 1:118,692,478...118,866,114

G

ATPase phospholipid transporting 11B (putative)

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP11B mRNA

NCBI chr 2:118,585,348...118,691,076
Ensembl chr 2:120,513,552...120,619,249

G

ATPase H+/K+ transporting non-gastric alpha2 subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP12A mRNA

NCBI chr15:34,559,209...34,583,866
Ensembl chr15:34,559,209...34,583,866

G

ATPase Na+/K+ transporting subunit alpha 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A1 mRNA

NCBI chr 2:191,709,311...191,737,414
Ensembl chr 2:191,709,311...191,737,425

G

ATPase Na+/K+ transporting subunit alpha 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1A3 mRNA

NCBI chr 1:89,700,645...89,729,782
Ensembl chr 1:89,700,649...89,729,825

G

ATPase Na+/K+ transporting subunit alpha 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1A4 mRNA

NCBI chr13:87,216,139...87,252,155
Ensembl chr13:87,216,139...87,251,724

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP1B1 mRNA

NCBI chr13:79,319,708...79,340,226
Ensembl chr13:79,319,706...79,340,549

G

ATPase Na+/K+ transporting subunit beta 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP1B3 mRNA

NCBI chr 8:105,789,824...105,821,151
Ensembl chr 8:65,253,361...65,254,304
Ensembl chr 8:65,253,361...65,254,304

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP2A1 mRNA

NCBI chr 1:181,026,606...181,044,859
Ensembl chr 1:190,457,198...190,475,423

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2A3 mRNA

NCBI chr10:57,581,742...57,612,758
Ensembl chr10:58,079,852...58,111,278

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP2B1 mRNA

NCBI chr 7:35,622,267...35,731,904
Ensembl chr 7:35,622,461...35,731,904

G

ATPase secretory pathway Ca2+ transporting 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ATP2C2 mRNA

NCBI chr19:64,662,729...64,719,998
Ensembl chr19:64,662,715...64,719,996

G

ATPase H+/K+ transporting subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP4B mRNA

NCBI chr16:76,144,150...76,153,063
Ensembl chr16:82,846,329...82,855,242

G

ATPase H+ transporting V0 subunit a2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V0A2 mRNA

NCBI chr12:31,947,220...31,979,875
Ensembl chr12:37,472,813...37,640,860

G

ATPase H+ transporting V0 subunit a4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0A4 mRNA

NCBI chr 4:66,760,163...66,842,126
Ensembl chr 4:67,727,145...67,809,092

G

ATPase H+ transporting V0 subunit D2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V0D2 mRNA

NCBI chr 5:33,336,257...33,385,354
Ensembl chr 5:38,133,158...38,182,245

G

ATPase H+ transporting V1 subunit E2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP6V1E2 mRNA

NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:13,404,848...13,456,037

G

ATPase H+ transporting V1 subunit G3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP6V1G3 mRNA

NCBI chr13:49,800,256...49,825,247
Ensembl chr13:52,351,801...52,375,594

G

ATPase copper transporting alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP7A mRNA

NCBI chr X:75,159,635...75,267,094
Ensembl chr X:75,159,782...75,267,093

G

ATPase phospholipid transporting 8B1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:60,288,464...60,427,027

G

ATPase phospholipid transporting 8B2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ATP8B2 mRNA

NCBI chr 2:177,676,205...177,699,575
Ensembl chr 2:177,676,208...177,699,575

G

arginine vasopressin receptor 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1A mRNA

NCBI chr 7:59,999,743...60,003,667
Ensembl chr 7:59,999,738...60,003,837

G

arginine vasopressin receptor 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of AVPR1B mRNA

NCBI chr13:43,046,531...43,059,046
Ensembl chr13:45,598,763...45,611,277

G

arginine vasopressin receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of AVPR2 mRNA

NCBI chr X:156,785,009...156,787,477
Ensembl chr X:156,785,139...156,787,477

G

axin 2

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of AXIN2 protein]

NCBI chr10:94,393,379...94,426,579
Ensembl chr10:94,395,909...94,426,575

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of B3GNT3 mRNA

NCBI chr16:18,401,405...18,410,821
Ensembl chr16:18,435,378...18,444,738

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of B3GNT8 mRNA

NCBI chr 1:81,135,602...81,138,501
Ensembl chr 1:90,263,827...90,270,287

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:68,646,203...68,656,181

G

BCL2 associated X, apoptosis regulator

decreases expression
increases expression
multiple interactions

EXP

Azoxymethane results in decreased expression of BAX protein
Azoxymethane results in increased expression of BAX mRNA
pinostrobin inhibits the reaction [Azoxymethane results in decreased expression of BAX protein]; xanthohumol inhibits the reaction [Azoxymethane results in decreased expression of BAX protein]

PMID:20043115 PMID:31714664 PMID:38078205

NCBI chr 1:105,076,472...105,081,906
Ensembl chr 1:105,076,473...105,086,429

G

BCL2, apoptosis regulator

multiple interactions
increases expression
affects expression

EXP
ISO

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of BCL2 protein]; Aspirin inhibits the reaction [Azoxymethane results in increased expression of BCL2 mRNA]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of BCL2 protein]; pinostrobin inhibits the reaction [Azoxymethane results in increased expression of BCL2 protein]; xanthohumol inhibits the reaction [Azoxymethane results in increased expression of BCL2 protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BCL2 protein]
Azoxymethane results in increased expression of BCL2 mRNA; Azoxymethane results in increased expression of BCL2 protein
Azoxymethane affects the expression of BCL2 mRNA; Azoxymethane affects the expression of BCL2 protein

PMID:17961945 PMID:20043115 PMID:22467055 PMID:25449198 PMID:31714664 More...

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 1

affects expression

EXP

Azoxymethane affects the expression of BCL2L1 mRNA

NCBI chr 3:161,713,777...161,764,844
Ensembl chr 3:161,745,540...161,764,907
Ensembl chr 1:161,745,540...161,764,907

G

bradykinin receptor B1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB1 mRNA

NCBI chr 6:130,275,631...130,284,968
Ensembl chr 6:130,275,478...130,280,973

G

bradykinin receptor B2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BDKRB2 mRNA

NCBI chr 6:130,237,055...130,267,205
Ensembl chr 6:130,237,255...130,267,209

G

bestrophin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BEST1 mRNA

NCBI chr 1:216,054,395...216,071,012
Ensembl chr 1:216,054,395...216,070,974

G

biglycan

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BGN mRNA

NCBI chr X:151,197,296...151,209,458
Ensembl chr X:156,348,615...156,360,799

G

baculoviral IAP repeat-containing 2

affects expression

EXP

Azoxymethane affects the expression of BIRC2 mRNA

NCBI chr 8:13,253,697...13,273,672
Ensembl chr 8:13,253,706...13,271,911

G

baculoviral IAP repeat-containing 5

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BIRC5 protein]

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

bone morphogenetic protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP1 mRNA

NCBI chr15:45,551,603...45,595,862
Ensembl chr15:51,961,310...52,005,485

G

bone morphogenetic protein 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP10 mRNA

NCBI chr 4:121,423,936...121,439,094
Ensembl chr 4:121,429,199...121,435,728

G

bone morphogenetic protein 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMP7 mRNA

NCBI chr 3:182,059,318...182,135,273
Ensembl chr 3:182,052,337...182,135,137

G

bone morphogenetic protein receptor type 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BMPR1B mRNA

NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311

G

bone morphogenetic protein receptor type 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:68,685,988...68,801,350

G

bone marrow stromal cell antigen 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of BST1 mRNA

NCBI chr14:71,466,179...71,482,671
Ensembl chr14:71,466,180...71,482,647

G

core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1 mRNA

NCBI chr 4:35,930,981...35,966,100
Ensembl chr 4:36,894,488...36,932,441

G

C1GALT1-specific chaperone 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of C1GALT1C1 mRNA

NCBI chr X:117,378,123...117,382,620
Ensembl chr X:122,234,454...122,248,422

G

complement C1q A chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QA mRNA

NCBI chr 5:149,133,635...149,136,482
Ensembl chr 5:154,417,087...154,427,732

G

complement C1q B chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1QB mRNA

NCBI chr 5:149,118,843...149,124,394
Ensembl chr 5:154,402,279...154,407,840

G

complement C1s

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C1S1 mRNA

NCBI chr 4:159,116,549...159,128,736
Ensembl chr 4:159,116,549...159,128,736

G

complement C3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3 mRNA

NCBI chr 9:2,174,412...2,201,339
Ensembl chr 9:2,174,412...2,201,339

G

complement C3a receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C3AR1 mRNA

NCBI chr 4:156,074,747...156,084,680
Ensembl chr 4:157,746,089...157,776,323

G

complement C4B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C4B mRNA

NCBI chr20:4,201,979...4,216,292
Ensembl chr20:4,201,961...4,216,289

G

complement C5a receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of C5AR1 mRNA

NCBI chr 1:86,077,309...86,088,001

G

calcium binding protein 39

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAB39 mRNA

NCBI chr 9:86,463,095...86,524,545
Ensembl chr 9:93,911,054...93,972,542

G

calcium voltage-gated channel subunit alpha1 F

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CACNA1F mRNA

NCBI chr X:17,539,992...17,568,308
Ensembl chr X:17,539,920...17,568,308

G

calcium voltage-gated channel subunit alpha1 S

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CACNA1S mRNA

NCBI chr13:47,493,949...47,564,194
Ensembl chr13:50,045,668...50,115,903

G

calcitonin-related polypeptide alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CALCA mRNA

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:178,312,638...178,317,529

G

calcitonin-related polypeptide, beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALCB mRNA

NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:178,399,785...178,404,654

G

calmodulin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CALM1 mRNA

NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:125,217,246...125,225,381

G

calcium/calmodulin-dependent protein kinase II gamma

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK2G mRNA

NCBI chr15:3,553,238...3,612,310
Ensembl chr15:3,553,294...3,612,310

G

calcium/calmodulin-dependent protein kinase IV

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMK4 mRNA

NCBI chr18:24,582,988...24,811,918
Ensembl chr18:24,857,146...25,077,193

G

calcium/calmodulin-dependent protein kinase kinase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CAMKK1 mRNA

NCBI chr10:57,637,335...57,660,498
Ensembl chr10:58,135,915...58,159,010

G

carbonic anhydrase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CAR2 mRNA

NCBI chr 2:88,462,883...88,478,012
Ensembl chr 2:88,462,872...88,478,064

G

caspase 3

multiple interactions
decreases expression

EXP
ISO

xanthohumol inhibits the reaction [Azoxymethane results in decreased expression of CASP3 protein]
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CASP3 mRNA

PMID:29950665 PMID:31714664

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

carbonyl reductase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:46,478,274...46,486,558

G

cholecystokinin B receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCKBR mRNA

NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745

G

C-C motif chemokine ligand 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL11 mRNA

NCBI chr10:67,525,975...67,530,576
Ensembl chr10:67,525,862...67,530,575

G

C-C motif chemokine ligand 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL2 mRNA

NCBI chr10:67,503,077...67,504,875
Ensembl chr10:67,503,077...67,504,875

G

C-C motif chemokine ligand 21

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL21A mRNA

NCBI chr 5:61,776,411...61,777,515
Ensembl chr 5:61,776,413...61,777,540

G

C-C motif chemokine ligand 24

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL24 mRNA

NCBI chr12:26,737,423...26,741,420
Ensembl chr12:26,737,439...26,750,924

G

C-C motif chemokine ligand 25

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL25 mRNA

NCBI chr12:2,707,398...2,716,571
Ensembl chr12:7,505,235...7,514,385

G

C-C motif chemokine ligand 28

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CCL28 mRNA

NCBI chr 2:53,334,071...53,358,709
Ensembl chr 2:53,334,071...53,358,709

G

C-C motif chemokine ligand 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL4 mRNA

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,950,289...68,965,722

G

C-C motif chemokine ligand 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCL7 mRNA

NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,514,091...67,515,947

G

cyclin D1

affects expression
increases expression
multiple interactions

EXP
ISO

Azoxymethane affects the expression of CCND1 mRNA; Azoxymethane affects the expression of CCND1 protein
Azoxymethane results in increased expression of CCND1 mRNA; Azoxymethane results in increased expression of CCND1 protein
[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CCND1 mRNA]; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CCND1 protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of CCND1 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of CCND1 protein]; Raloxifene Hydrochloride affects the reaction [Azoxymethane affects the expression of CCND1 mRNA]; Raloxifene Hydrochloride affects the reaction [Azoxymethane affects the expression of CCND1 protein]; Ro 24-5531 inhibits the reaction [Azoxymethane results in increased expression of CCND1 mRNA]; Ro 24-5531 inhibits the reaction [Azoxymethane results in increased expression of CCND1 protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of CCND1 protein]; xanthohumol inhibits the reaction [Azoxymethane results in increased expression of CCND1 protein]
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CCND1 protein]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of CCND1 mRNA]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of CCND1 protein]

PMID:12496057 PMID:20681671 PMID:24080207 PMID:31714664 PMID:31715269

NCBI chr 1:209,518,288...209,527,986
Ensembl chr 1:209,518,288...209,527,810

G

C-C motif chemokine receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR2 mRNA

NCBI chr 8:132,611,883...132,619,106
Ensembl chr 8:132,611,410...132,620,059

G

C-C motif chemokine receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR4 mRNA

NCBI chr 8:114,176,291...114,182,033
Ensembl chr 8:123,054,324...123,077,642

G

C-C motif chemokine receptor 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR5 mRNA

NCBI chr 8:132,629,097...132,660,980
Ensembl chr 8:132,629,683...132,637,594

G

C-C motif chemokine receptor 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCR8 mRNA

NCBI chr 8:119,826,332...119,828,292
Ensembl chr 8:128,702,349...128,705,955

G

C-C motif chemokine receptor like 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CCRL2 mRNA

NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:119,911,288...119,922,380

G

CD180 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD180 mRNA

NCBI chr 2:33,855,940...33,870,046
Ensembl chr 2:35,589,451...35,603,982

G

Cd200 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD200 mRNA

NCBI chr11:55,410,166...55,437,527
Ensembl chr11:68,916,224...68,943,569

G

Cd247 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD247 mRNA

NCBI chr13:78,043,302...78,118,437
Ensembl chr13:80,576,202...80,655,248

G

CD274 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD274 mRNA

NCBI chr 1:227,116,674...227,137,379
Ensembl chr 1:236,496,463...236,549,951

G

Cd28 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD28 mRNA

NCBI chr 9:69,660,316...69,689,192
Ensembl chr 9:69,545,326...69,689,192

G

Cd4 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD4 mRNA

NCBI chr 4:159,355,147...159,381,636
Ensembl chr 4:159,356,337...159,381,461

G

CD55 molecule (Cromer blood group)

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD55 mRNA

NCBI chr13:44,409,574...44,438,913
Ensembl chr13:44,409,587...44,438,107

G

CD86 molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CD86 mRNA

NCBI chr11:77,647,565...77,706,178
Ensembl chr11:77,647,600...77,725,361

G

cytidine deaminase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDA mRNA

NCBI chr 5:150,556,615...150,583,231
Ensembl chr 5:155,839,929...155,866,541

G

cadherin 1

increases expression
multiple interactions
decreases expression

EXP
ISO

Azoxymethane results in increased expression of CDH1 protein
Ro 24-5531 inhibits the reaction [Azoxymethane results in increased expression of CDH1 protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of CDH1 protein]
Azoxymethane results in decreased expression of CDH1 protein
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH1 mRNA; pterostilbene inhibits the reaction [Azoxymethane results in decreased expression of CDH1 protein]

PMID:12496057 PMID:20681671 PMID:29950665 PMID:34273909

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 2

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CDH2 protein

NCBI chr18:8,051,097...8,265,288
Ensembl chr18:8,051,097...8,265,288

G

cadherin 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDH5 mRNA

NCBI chr19:821,875...860,931
Ensembl chr19:822,464...860,822

G

cyclin dependent kinase 2

affects expression
multiple interactions

EXP

Azoxymethane affects the expression of CDK2 protein
[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CDK2 protein]

NCBI chr 7:1,714,392...1,721,964
Ensembl chr 7:1,714,392...1,721,878

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
affects expression

EXP

[Azoxymethane co-treated with Sulindac] results in increased expression of CDKN1A protein; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CDKN1A protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of CDKN1A protein]
Azoxymethane affects the expression of CDKN1A mRNA; Azoxymethane affects the expression of CDKN1A protein

PMID:17961945 PMID:18644992 PMID:24080207

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 1B

multiple interactions
decreases expression

EXP

Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein]; Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein]; Sulindac inhibits the reaction [Azoxymethane results in decreased expression of CDKN1B protein]
Azoxymethane results in decreased expression of CDKN1B mRNA; Azoxymethane results in decreased expression of CDKN1B protein

NCBI chr 4:169,491,273...169,496,500
Ensembl chr 4:169,490,876...169,496,498

G

cyclin-dependent kinase inhibitor 1C

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:208,084,787...208,087,498

G

cyclin-dependent kinase inhibitor 2A

decreases expression
multiple interactions

EXP

Azoxymethane results in decreased expression of CDKN2A mRNA; Azoxymethane results in decreased expression of CDKN2A protein
Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]; Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]; Piroxicam inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A protein]; Sulindac inhibits the reaction [Azoxymethane results in decreased expression of CDKN2A mRNA]

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

carboxyl ester lipase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CEL mRNA

NCBI chr 3:11,883,532...11,891,035
Ensembl chr 3:32,281,518...32,289,019

G

carboxylesterase 1D

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES1D mRNA

NCBI chr19:30,046,494...30,085,039
Ensembl chr19:30,046,449...30,085,449

G

carboxylesterase 2C

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2C mRNA

NCBI chr 1:260,391,190...260,398,757
Ensembl chr 1:270,374,913...270,384,801

G

carboxylesterase 2E

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CES2E mRNA

NCBI chr19:157,447...172,822
Ensembl chr19:163,859...179,308

G

complement factor H

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CFH mRNA

NCBI chr13:54,063,079...54,164,523
Ensembl chr13:54,062,531...54,164,532

G

CASP8 and FADD-like apoptosis regulator

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFLAR protein]

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:67,679,559...67,726,434

G

CF transmembrane conductance regulator

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CFTR mRNA

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

chimerin 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHN2 mRNA

NCBI chr 4:83,148,616...83,407,711
Ensembl chr 4:84,704,862...84,738,068

G

cholinergic receptor, muscarinic 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRM4 mRNA

NCBI chr 3:77,893,425...77,901,166
Ensembl chr 3:98,348,650...98,358,771

G

cholinergic receptor nicotinic alpha 2 subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA2 mRNA

NCBI chr15:44,517,862...44,534,144
Ensembl chr15:44,517,862...44,534,144

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNA7 mRNA

NCBI chr 1:126,123,425...126,249,181
Ensembl chr 1:126,123,425...126,446,858

G

cholinergic receptor nicotinic beta 3 subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CHRNB3 mRNA

NCBI chr16:71,411,847...71,454,225
Ensembl chr16:71,417,039...71,454,225

G

cholinergic receptor nicotinic epsilon subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHRNE mRNA

NCBI chr10:55,331,211...55,339,923
Ensembl chr10:55,829,836...55,834,154

G

carbohydrate sulfotransferase 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CHST11 mRNA

NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:22,415,686...22,630,441

G

chloride channel accessory 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCA1 mRNA

NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:236,599,022...236,624,714

G

chloride voltage-gated channel 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN2 mRNA

NCBI chr11:93,702,382...93,716,059
Ensembl chr11:93,702,360...93,716,059

G

chloride voltage-gated channel 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CLCN3 mRNA

NCBI chr16:29,127,152...29,200,133
Ensembl chr16:34,137,952...34,210,984

G

claudin 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CLDN11 mRNA

NCBI chr 2:112,207,745...112,221,050
Ensembl chr 2:114,136,234...114,149,539

G

chymase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CMA1 mRNA

NCBI chr15:33,387,351...33,390,133
Ensembl chr15:33,387,351...33,390,133

G

cytidine monophosphate N-acetylneuraminic acid synthetase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CMAS mRNA

NCBI chr 4:175,718,808...175,737,128
Ensembl chr 4:177,449,732...177,476,291

G

cyclic nucleotide gated channel subunit alpha 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNGA4 mRNA

NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:169,164,206...169,168,224

G

cannabinoid receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CNR2 mRNA; CNR2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]

PMID:29950665 PMID:32942172

NCBI chr 5:153,408,968...153,435,092
Ensembl chr 5:153,409,147...153,435,961

G

ciliary neurotrophic factor receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTFR mRNA

NCBI chr 5:56,823,448...56,861,049
Ensembl chr 5:61,619,326...61,645,795

G

contactin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CNTN1 mRNA

NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:125,142,696...125,440,391

G

collagen type XI alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL11A1 mRNA

NCBI chr 2:204,509,136...204,702,264
Ensembl chr 2:204,509,136...204,702,264

G

collagen type XIV alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL14A1 mRNA

NCBI chr 7:86,722,093...86,937,215
Ensembl chr 7:88,611,828...88,826,938

G

collagen type XVIII alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL18A1 mRNA

NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,473,645...11,582,112

G

collagen type I alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL1A1 mRNA

NCBI chr10:80,380,458...80,397,461
Ensembl chr10:80,380,453...80,397,460

G

collagen type XXIII alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL23A1 mRNA

NCBI chr10:35,549,090...35,839,152
Ensembl chr10:36,050,259...36,337,897

G

collagen type XXVIII alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL28A1 mRNA

NCBI chr 4:36,069,980...36,223,128
Ensembl chr 4:37,035,761...37,189,494

G

collagen type IV alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A1 mRNA

NCBI chr16:84,885,597...84,996,482
Ensembl chr16:84,885,597...84,996,482

G

collagen type IV alpha 2 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL4A2 mRNA

NCBI chr16:78,047,591...78,183,360
Ensembl chr16:84,749,672...84,885,520

G

collagen type V alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A1 mRNA

NCBI chr 3:31,606,475...31,755,097
Ensembl chr 3:31,606,486...31,753,020

G

collagen type V alpha 2 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL5A2 mRNA

NCBI chr 9:47,448,741...47,598,134
Ensembl chr 9:54,940,764...55,090,150

G

collagen type VIII alpha 1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of COL8A1 mRNA

NCBI chr11:42,776,851...42,906,432
Ensembl chr11:56,369,868...56,376,229

G

ceruloplasmin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:104,368,456...104,427,087

G

carboxypeptidase A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CPA1 mRNA

NCBI chr 4:59,257,417...59,263,544
Ensembl chr 4:60,224,801...60,230,928

G

carboxypeptidase B2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CPB2 mRNA

NCBI chr15:50,557,722...50,606,569
Ensembl chr15:56,966,839...57,015,962

G

corticotropin releasing hormone receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CRHR1 mRNA

NCBI chr10:89,540,192...89,583,466
Ensembl chr10:89,540,192...89,583,466

G

corticotropin releasing hormone receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRHR2 mRNA

NCBI chr 4:85,553,163...85,596,203
Ensembl chr 4:85,554,268...85,596,318

G

cartilage associated protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CRTAP mRNA

NCBI chr 8:114,047,929...114,067,636
Ensembl chr 8:122,926,117...122,945,843

G

colony stimulating factor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF1 mRNA

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:198,065,405...198,084,468

G

colony stimulating factor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2 mRNA

NCBI chr10:38,887,692...38,889,673
Ensembl chr10:38,887,692...38,890,031

G

colony stimulating factor 2 receptor subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CSF2RB2 mRNA

NCBI chr 7:111,756,950...111,782,089
Ensembl chr 7:111,757,405...111,784,654

G

colony stimulating factor 3 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CSF3R mRNA

NCBI chr 5:143,583,126...143,604,382
Ensembl chr 5:143,583,213...143,602,411

G

C-terminal Src kinase

multiple interactions

EXP

[[Azoxymethane co-treated with Sulindac] results in increased expression of CSK protein] which results in increased phosphorylation of and results in decreased activity of SRC protein; [Azoxymethane co-treated with Sulindac] results in increased expression of CSK protein

NCBI chr 8:66,925,650...66,944,861
Ensembl chr 8:66,925,651...66,930,274

G

catenin beta 1

affects expression
multiple interactions

EXP
ISO

Azoxymethane affects the expression of CTNNB1 mRNA; Azoxymethane affects the expression of CTNNB1 protein
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of CTNNB1 protein]
[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CTNNB1 mRNA]; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of CTNNB1 protein]; Azoxymethane results in decreased phosphorylation of and results in increased activity of CTNNB1 protein; Bexarotene affects the reaction [Azoxymethane affects the expression of CTNNB1 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of CTNNB1 protein]; xanthohumol inhibits the reaction [Azoxymethane results in decreased phosphorylation of and results in increased activity of CTNNB1 protein]

PMID:24080207 PMID:31714664 PMID:31715269

NCBI chr 8:129,517,576...129,544,661
Ensembl chr 8:129,517,545...129,544,662

G

cathepsin K

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSK mRNA

NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582

G

cathepsin L

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CTSL mRNA

NCBI chr17:770,104...776,266
Ensembl chr17:770,093...777,113

G

cubilin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CUBN mRNA

NCBI chr17:76,385,046...76,593,133
Ensembl chr17:81,293,619...81,501,694

G

C-X3-C motif chemokine receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CX3CR1 mRNA

NCBI chr 8:128,661,294...128,679,048
Ensembl chr 8:128,654,833...128,685,983

G

CXADR, Ig-like cell adhesion molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXADR mRNA

NCBI chr11:30,469,778...30,516,990
Ensembl chr11:30,469,526...30,516,988

G

C-X-C motif chemokine ligand 10

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL10 mRNA]

NCBI chr14:15,989,066...15,991,263
Ensembl chr14:15,989,018...15,991,261

G

C-X-C motif chemokine ligand 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL14 mRNA

NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172

G

C-X-C motif chemokine ligand 3

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CXCL1 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL1 mRNA

PMID:29950665 PMID:34273909

NCBI chr14:17,571,900...17,573,624
Ensembl chr14:17,571,900...17,573,624

G

C-X-C motif chemokine ligand 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCL5 mRNA

NCBI chr14:17,594,959...17,596,417
Ensembl chr14:17,594,959...17,596,417

G

C-X-C motif chemokine receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CXCR2 mRNA

NCBI chr 9:83,178,645...83,185,017
Ensembl chr 9:83,183,808...83,188,602

G

cytoplasmic FMR1 interacting protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP1 mRNA

NCBI chr 1:115,842,754...115,935,163
Ensembl chr 1:115,846,661...115,951,292

G

cytoplasmic FMR1 interacting protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYFIP2 mRNA

NCBI chr10:31,122,653...31,242,440
Ensembl chr10:31,122,653...31,242,440

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases expression

ISO

Azoxymethane results in decreased expression of CYP1A2 mRNA

NCBI chr 8:66,971,261...66,978,149
Ensembl chr 8:66,971,261...66,978,149

G

cytochrome P450, family 27, subfamily b, polypeptide 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP27B1 mRNA

NCBI chr 7:62,869,340...62,876,242
Ensembl chr 7:64,756,626...64,761,570

G

cytochrome P450, family 2, subfamily b, polypeptide 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2B13 mRNA

NCBI chr 1:90,722,243...90,736,272

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP2B10 mRNA

NCBI chr 1:90,780,468...90,859,852

G

cytochrome P450, family 2, subfamily c, polypeptide 24

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C55 mRNA

NCBI chr 1:236,873,967...236,936,238
Ensembl chr 1:246,286,341...246,348,607

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C29 mRNA

NCBI chr 1:247,879,058...247,916,804
Ensembl chr 1:247,879,078...247,916,798

G

cytochrome P450, family 2, subfamily c, polypeptide 66

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2C66 mRNA

NCBI chr 1:237,078,517...237,169,841
Ensembl chr 1:248,272,336...248,309,323

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases expression

ISO

Azoxymethane results in decreased expression of CYP2E1 mRNA

NCBI chr 1:205,269,967...205,280,365
Ensembl chr 1:205,267,505...205,293,495

G

cytochrome P450, family 2, subfamily j, polypeptide 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2J9 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:116,295,694...116,323,042

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2R1 mRNA

NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:178,219,704...178,232,423

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP2S1 mRNA

NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:90,438,224...90,453,073

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP3A13 mRNA

NCBI chr12:21,919,955...21,960,160
Ensembl chr12:21,919,940...21,960,154

G

cytochrome P450, family 4, subfamily b, polypeptide 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4B1 mRNA

NCBI chr 5:134,375,807...134,413,635
Ensembl chr 5:134,375,807...134,393,116

G

cytochrome P450, family 4, subfamily f, polypeptide 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of CYP4F14 mRNA

NCBI chr 7:12,010,850...12,022,497
Ensembl chr 7:12,661,359...12,672,612

G

cytochrome P450, family 4, subfamily f, polypeptide 39

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP4F39 mRNA

NCBI chr 7:11,426,806...11,505,553
Ensembl chr 7:12,083,888...12,156,076

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:102,419,011...102,586,047
Ensembl chr 2:102,419,011...102,451,804

G

decorin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DCN mRNA

NCBI chr 7:34,167,973...34,208,004
Ensembl chr 7:34,163,011...34,218,926

G

discoidin domain receptor tyrosine kinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DDR2 mRNA

NCBI chr13:82,193,623...82,318,229
Ensembl chr13:84,731,180...84,850,288

G

diacylglycerol kinase, beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DGKB mRNA

NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:60,368,519...61,124,420

G

diacylglycerol kinase, iota

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DGKI mRNA

NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:66,387,126...66,990,832

G

dickkopf WNT signaling pathway inhibitor 2

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of DKK2 mRNA]

NCBI chr 2:220,568,338...220,660,225
Ensembl chr 2:223,242,377...223,334,724

G

delta like non-canonical Notch ligand 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DLK1 mRNA

NCBI chr 6:128,410,216...128,417,518
Ensembl chr 6:134,192,518...134,200,529

G

dynamin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM1 mRNA

NCBI chr 3:15,604,782...15,648,654
Ensembl chr 3:36,002,064...36,046,289

G

dynamin 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DNM3 mRNA

NCBI chr13:74,359,043...74,838,135
Ensembl chr13:76,892,171...77,371,350

G

docking protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DOK2 mRNA

NCBI chr15:45,826,984...45,841,409
Ensembl chr15:52,236,900...52,251,074

G

dipeptidase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DPEP2 mRNA

NCBI chr19:33,883,557...33,896,487
Ensembl chr19:50,795,327...50,801,757
Ensembl chr19:50,795,327...50,801,757

G

dihydropyrimidine dehydrogenase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DPYD mRNA

NCBI chr 2:209,293,902...210,159,777
Ensembl chr 2:209,293,929...210,159,778

G

dopamine receptor D4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD4 mRNA

NCBI chr 1:205,825,937...205,829,124
Ensembl chr 1:205,826,049...205,830,458

G

dopamine receptor D5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of DRD5 mRNA

NCBI chr14:72,487,950...72,491,050
Ensembl chr14:76,700,241...76,703,466

G

deltex E3 ubiquitin ligase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of DTX1 mRNA

NCBI chr12:35,849,647...35,880,835
Ensembl chr12:41,510,264...41,541,430

G

dual specificity phosphatase 1

multiple interactions

ISO

DUSP1 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]

NCBI chr10:17,184,853...17,187,646
Ensembl chr10:17,184,823...17,187,644

G

enoyl-CoA delta isomerase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ECI1 mRNA

NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,961,218...13,974,773

G

ectodysplasin-A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA mRNA

NCBI chr X:69,118,577...69,520,274
Ensembl chr X:69,118,796...69,520,274

G

ectodysplasin A2 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDA2R mRNA

NCBI chr X:62,224,763...62,269,333
Ensembl chr X:66,236,111...66,280,663

G

endothelin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDN1 mRNA

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EDN2 mRNA

NCBI chr 5:133,751,316...133,756,814
Ensembl chr 5:139,036,492...139,043,070

G

endothelin receptor type A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EDNRA mRNA

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

EGF containing fibulin extracellular matrix protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EFEMP2 mRNA

NCBI chr 1:202,781,692...202,789,784
Ensembl chr 1:212,210,972...212,218,739

G

enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of EHHADH mRNA

NCBI chr11:79,241,927...79,275,173
Ensembl chr11:92,746,420...92,779,662

G

elastase, neutrophil expressed

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELANE mRNA

NCBI chr 7:10,467,877...10,469,725
Ensembl chr 7:10,467,877...10,469,725

G

engulfment and cell motility 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ELMO2 mRNA

NCBI chr 3:154,023,661...154,061,259
Ensembl chr 3:174,442,965...174,480,459

G

E1A binding protein p300

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EP300 mRNA

NCBI chr 7:114,987,857...115,058,652
Ensembl chr 7:114,946,982...115,058,574

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB2 mRNA

NCBI chr10:83,907,491...83,931,365
Ensembl chr10:83,907,460...83,931,481

G

erb-b2 receptor tyrosine kinase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ERBB3 mRNA

NCBI chr 7:1,579,079...1,600,379
Ensembl chr 7:1,579,816...1,601,120

G

erb-b2 receptor tyrosine kinase 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ERBB4 mRNA

NCBI chr 9:76,973,386...78,045,633
Ensembl chr 9:76,973,227...78,045,772

G

endothelial cell adhesion molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESAM mRNA

NCBI chr 8:45,426,985...45,437,976
Ensembl chr 8:45,425,731...45,437,973

G

estrogen receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ESR1 mRNA

NCBI chr 1:43,511,685...43,904,454
Ensembl chr 1:43,644,392...43,900,354

G

estrogen receptor 2

affects expression
multiple interactions

EXP

Azoxymethane affects the expression of ESR2 mRNA; Azoxymethane affects the expression of ESR2 protein
[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of ESR2 mRNA]; [Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of ESR2 protein]; Bexarotene affects the reaction [Azoxymethane affects the expression of ESR2 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of ESR2 protein]; Raloxifene Hydrochloride affects the reaction [Azoxymethane affects the expression of ESR2 mRNA]; Raloxifene Hydrochloride affects the reaction [Azoxymethane affects the expression of ESR2 protein]

NCBI chr 6:100,589,553...100,645,240
Ensembl chr 6:100,545,206...100,644,709

G

Enah/Vasp-like

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of EVL mRNA

NCBI chr 6:133,238,547...133,358,730
Ensembl chr 6:133,238,547...133,358,729

G

coagulation factor X

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F10 mRNA

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:83,170,977...83,190,280

G

coagulation factor XIII A1 chain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F13A1 mRNA

NCBI chr17:28,021,197...28,197,960
Ensembl chr17:28,020,845...28,197,948

G

coagulation factor II (thrombin) receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F2R mRNA

NCBI chr 2:26,869,343...26,885,856
Ensembl chr 2:28,604,066...28,620,579

G

F2R like trypsin receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of F2RL1 mRNA

NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954

G

coagulation factor V

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of F5 mRNA

NCBI chr13:79,046,657...79,116,247
Ensembl chr13:79,046,448...79,116,247

G

fatty acid binding protein 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FABP6 mRNA

NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,565,054...28,573,058

G

Fas cell surface death receptor

increases expression
multiple interactions

EXP

Azoxymethane results in increased expression of FAS mRNA
Aspirin inhibits the reaction [Azoxymethane results in increased expression of FAS mRNA]

NCBI chr 1:241,212,155...241,245,774
Ensembl chr 1:241,205,935...241,246,104

G

Fas ligand

increases expression
multiple interactions

ISO
EXP

Azoxymethane results in increased expression of FASLG protein
Aspirin inhibits the reaction [Azoxymethane results in increased expression of FASLG mRNA]
Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of FASLG protein]

PMID:20043115 PMID:20431929

NCBI chr13:76,680,885...76,706,042
Ensembl chr13:76,688,243...76,695,503

G

fibulin 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN2 mRNA

NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:125,261,607...125,321,029

G

fibulin 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBLN5 mRNA

NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:126,664,100...126,746,296

G

fibrillin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:133,008,361...133,204,283

G

Fc epsilon receptor Ig

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCER1G mRNA

NCBI chr13:83,649,447...83,654,248
Ensembl chr13:86,181,908...86,186,859

G

Fc gamma receptor 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR1 mRNA

NCBI chr 2:186,539,941...186,548,941
Ensembl chr 2:186,539,942...186,548,858

G

Fc gamma receptor 2A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR3 mRNA

NCBI chr13:85,813,516...85,830,269
Ensembl chr13:85,855,437...85,864,394
Ensembl chr13:85,855,437...85,864,394

G

Fc gamma receptor 2B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR2B mRNA

NCBI chr13:85,725,897...85,740,517
Ensembl chr13:85,725,897...85,740,517

G

Fc gamma receptor 3A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FCGR4 mRNA

NCBI chr13:85,782,636...85,792,656
Ensembl chr13:85,782,490...85,792,651

G

fucose kinase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FCSK mRNA

NCBI chr19:38,849,130...38,874,497
Ensembl chr19:55,739,842...55,800,496

G

free fatty acid receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR2 mRNA

NCBI chr 1:95,199,277...95,202,599
Ensembl chr 1:95,199,271...95,202,623

G

free fatty acid receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FFAR4 mRNA

NCBI chr 1:245,286,009...245,304,029
Ensembl chr 1:245,285,883...245,304,031

G

fibroblast growth factor 18

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF18 mRNA

NCBI chr10:17,706,011...17,737,702
Ensembl chr10:18,210,512...18,240,933

G

fibroblast growth factor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGF2 mRNA

NCBI chr 2:122,164,454...122,218,796
Ensembl chr 2:122,164,454...122,224,493

G

fibroblast growth factor 23

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF23 mRNA

NCBI chr 4:159,914,267...159,923,821
Ensembl chr 4:161,600,383...161,609,991

G

fibroblast growth factor 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF8 mRNA

NCBI chr 1:254,533,504...254,539,605
Ensembl chr 1:254,533,504...254,539,605

G

fibroblast growth factor 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FGF9 mRNA

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:36,325,599...36,367,926

G

Fibroblast growth factor receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FGFR1 mRNA

NCBI chr16:73,194,631...73,249,855
Ensembl chr16:73,194,631...73,249,855

G

Fms related receptor tyrosine kinase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT1 mRNA

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:12,333,430...12,504,750

G

Fms related receptor tyrosine kinase 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FLT4 mRNA

NCBI chr10:33,913,725...33,954,770
Ensembl chr10:34,414,733...34,456,645

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:77,715,402...77,747,874

G

fibromodulin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FMOD mRNA

NCBI chr13:45,493,517...45,504,134
Ensembl chr13:47,990,774...48,056,183

G

fibronectin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FN1 mRNA

NCBI chr 9:80,645,507...80,714,200
Ensembl chr 9:80,645,507...80,714,137

G

folate receptor alpha

increases response to substance

ISO

FOLR1 gene mutant form results in increased susceptibility to Azoxymethane

NCBI chr 1:165,631,462...165,650,430
Ensembl chr 1:165,631,462...165,642,669

G

forkhead box A2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA2 mRNA

NCBI chr 3:135,470,123...135,474,326
Ensembl chr 3:155,923,307...155,928,757

G

forkhead box A3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXA3 mRNA

NCBI chr 1:78,662,067...78,672,321
Ensembl chr 1:87,790,012...87,800,953

G

forkhead box O3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FOXO3 mRNA

NCBI chr20:47,251,968...47,348,254
Ensembl chr20:47,255,878...47,346,845

G

forkhead box O4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FOXO4 mRNA

NCBI chr X:66,385,241...66,392,115
Ensembl chr X:70,425,563...70,432,120

G

fucose-1-phosphate guanylyltransferase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPGT mRNA

NCBI chr 2:244,099,031...244,119,967
Ensembl chr 2:246,757,986...246,778,848

G

formyl peptide receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR1 mRNA

NCBI chr 1:58,745,019...58,756,776
Ensembl chr 1:67,421,313...67,422,520

G

formyl peptide receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FPR2 mRNA

NCBI chr 1:58,776,592...58,785,227
Ensembl chr 1:67,449,637...67,458,272

G

formyl peptide receptor 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FPR3 mRNA

NCBI chr 1:58,884,427...58,893,472
Ensembl chr 1:67,518,199...67,566,519

G

follicle stimulating hormone receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSHR mRNA

NCBI chr 6:10,952,329...11,160,288
Ensembl chr 6:10,952,329...11,160,288

G

follistatin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FST mRNA

NCBI chr 2:46,123,260...46,130,584
Ensembl chr 2:47,856,345...47,863,491

G

follistatin like 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FSTL3 mRNA

NCBI chr 7:10,574,195...10,579,844
Ensembl chr 7:10,574,186...10,590,509

G

ferritin heavy chain 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FTH1 protein; sinpeinine A inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FTH1 protein]

NCBI chr 1:216,052,037...216,054,325
Ensembl chr 1:216,051,998...216,055,214

G

FXYD domain-containing ion transport regulator 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD1 mRNA

NCBI chr 1:86,287,163...86,291,478
Ensembl chr 1:95,414,557...95,418,591

G

FXYD domain-containing ion transport regulator 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD3 mRNA

NCBI chr 1:95,432,918...95,440,129
Ensembl chr 1:95,432,919...95,439,702

G

FXYD domain-containing ion transport regulator 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FXYD4 mRNA

NCBI chr 4:152,782,181...152,786,118
Ensembl chr 4:152,782,181...152,786,039

G

FYN proto-oncogene, Src family tyrosine kinase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FYN mRNA

NCBI chr20:44,322,635...44,514,498
Ensembl chr20:44,322,361...44,515,479

G

frizzled class receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD1 mRNA

NCBI chr 4:30,265,074...30,269,472
Ensembl chr 4:30,247,228...30,833,176

G

frizzled class receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD4 mRNA

NCBI chr 1:152,692,507...152,701,372
Ensembl chr 1:152,692,507...152,701,372

G

frizzled class receptor 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD5 mRNA

NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612

G

frizzled class receptor 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD6 mRNA

NCBI chr 7:71,939,916...71,971,685
Ensembl chr 7:71,939,973...71,971,680

G

frizzled class receptor 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of FZD7 mRNA

NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585

G

frizzled class receptor 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of FZD8 mRNA

NCBI chr17:62,007,849...62,015,485
Ensembl chr17:62,007,627...62,015,961

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,757,899...86,818,033

G

gamma-aminobutyric acid type B receptor subunit 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GABBR1 mRNA

NCBI chr20:1,469,779...1,499,352
Ensembl chr20:1,469,779...1,498,607

G

gamma-aminobutyric acid type A receptor subunit alpha 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA2 mRNA

NCBI chr14:37,097,251...37,230,030
Ensembl chr14:37,450,683...37,587,457

G

gamma-aminobutyric acid type A receptor subunit alpha 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRA5 mRNA

NCBI chr 1:108,268,728...108,381,670
Ensembl chr 1:117,404,494...117,516,635

G

gamma-aminobutyric acid type A receptor subunit beta 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRB2 mRNA

NCBI chr10:26,936,592...27,156,141
Ensembl chr10:27,438,238...27,655,171

G

gamma-aminobutyric acid type A receptor subunit delta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GABRD mRNA

NCBI chr 5:165,958,508...165,970,407
Ensembl chr 5:171,240,789...171,253,094

G

glutamate decarboxylase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAD1 mRNA

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:75,777,534...75,818,759

G

UDP-galactose-4-epimerase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALE mRNA

NCBI chr 5:148,193,886...148,198,392
Ensembl chr 5:153,478,325...153,481,922

G

galactokinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALK2 mRNA

NCBI chr 3:113,110,057...113,243,014
Ensembl chr 3:133,563,538...133,696,528

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT10 mRNA

NCBI chr10:41,821,216...41,967,618
Ensembl chr10:42,322,161...42,468,087

G

polypeptide N-acetylgalactosaminyltransferase 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT12 mRNA

NCBI chr 5:61,384,575...61,413,346
Ensembl chr 5:66,180,164...66,208,938

G

polypeptide N-acetylgalactosaminyltransferase 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT15 mRNA

NCBI chr16:7,227,232...7,267,002
Ensembl chr16:7,233,606...7,273,285

G

polypeptide N-acetylgalactosaminyltransferase 16

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT16 mRNA

NCBI chr 6:100,168,943...100,250,718
Ensembl chr 6:105,901,153...105,991,350

G

polypeptide N-acetylgalactosaminyltransferase 18

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT18 mRNA

NCBI chr 1:165,593,180...165,904,268
Ensembl chr 1:175,027,839...175,338,883

G

polypeptide N-acetylgalactosaminyltransferase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GALNT2 mRNA

NCBI chr19:52,213,226...52,324,816
Ensembl chr19:69,110,657...69,222,237

G

polypeptide N-acetylgalactosaminyltransferase 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT4 mRNA

NCBI chr 7:33,925,229...33,927,770

G

polypeptide N-acetylgalactosaminyltransferase 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT5 mRNA

NCBI chr 3:42,573,622...42,619,881
Ensembl chr 3:62,982,465...63,028,724

G

polypeptide N-acetylgalactosaminyltransferase 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT6 mRNA

NCBI chr 7:131,789,836...131,828,077
Ensembl chr 7:133,668,615...133,698,439

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:37,589,425...37,713,909

G

polypeptide N-acetylgalactosaminyltransferase-like 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GALNTL6 mRNA

NCBI chr16:31,192,880...32,443,979
Ensembl chr16:36,204,614...37,452,780

G

gastrin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GAST mRNA

NCBI chr10:85,264,832...85,269,393
Ensembl chr10:85,765,216...85,767,880

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLC mRNA

NCBI chr 8:87,510,251...87,548,896
Ensembl chr 8:87,510,463...87,548,893

G

glutamate cysteine ligase, modifier subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCLM mRNA

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:213,031,838...213,055,003

G

glucosaminyl (N-acetyl) transferase 3, mucin type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GCNT3 mRNA

NCBI chr 8:70,689,173...70,696,476
Ensembl chr 8:79,566,753...79,581,595

G

glutamine fructose-6-phosphate transaminase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFPT1 mRNA

NCBI chr 4:119,496,691...119,546,472
Ensembl chr 4:121,054,045...121,103,799

G

glutamine-fructose-6-phosphate transaminase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GFPT2 mRNA

NCBI chr10:34,115,005...34,161,329
Ensembl chr10:34,615,370...34,662,419

G

GDP-L-fucose synthase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GFUS mRNA

NCBI chr 7:109,492,808...109,497,719
Ensembl chr 7:109,492,809...109,497,662

G

gamma-glutamyl cyclotransferase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GGCT mRNA

NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:85,453,387...85,470,224

G

growth hormone 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GH mRNA

NCBI chr10:91,727,883...91,729,860
Ensembl chr10:91,727,884...91,729,859

G

ghrelin and obestatin prepropeptide

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GHRL mRNA

NCBI chr 4:148,421,315...148,431,128
Ensembl chr 4:148,421,315...148,425,969

G

GLI family zinc finger 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLI3 mRNA

NCBI chr17:54,134,064...54,405,198
Ensembl chr17:54,134,064...54,405,198

G

glucagon-like peptide 1 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GLP1R mRNA

NCBI chr20:8,973,393...9,011,622
Ensembl chr20:8,973,352...9,011,654

G

GDP-mannose 4, 6-dehydratase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GMDS mRNA

NCBI chr17:32,095,315...32,621,975
Ensembl chr17:32,304,056...32,830,706

G

G protein subunit alpha 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA11 mRNA

NCBI chr 7:8,814,285...8,828,628
Ensembl chr 7:8,814,327...8,830,558

G

G protein subunit alpha 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA12 mRNA

NCBI chr12:13,805,580...13,886,255
Ensembl chr12:18,919,629...19,000,185

G

G protein subunit alpha 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNA14 mRNA

NCBI chr 1:213,714,993...213,900,083
Ensembl chr 1:223,141,802...223,324,210

G

G protein subunit alpha 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNA15 mRNA

NCBI chr 7:8,184,632...8,205,508
Ensembl chr 7:8,835,357...8,856,268

G

G protein subunit alpha z

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNAZ mRNA

NCBI chr20:13,643,473...13,694,240
Ensembl chr20:13,644,020...13,669,287

G

G protein subunit beta 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNB3 mRNA

NCBI chr 4:157,639,468...157,645,171
Ensembl chr 4:159,325,742...159,331,445

G

glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNE mRNA

NCBI chr 5:58,267,189...58,307,396
Ensembl chr 5:63,062,850...63,103,251

G

G protein subunit gamma 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG4 mRNA

NCBI chr17:93,432,791...93,481,709
Ensembl chr17:93,433,195...93,481,709

G

G protein subunit gamma 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG7 mRNA

NCBI chr 7:8,697,458...8,761,239
Ensembl chr 7:9,348,218...9,411,923

G

G protein subunit gamma 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNG8 mRNA

NCBI chr 1:77,564,512...77,568,371
Ensembl chr 1:86,692,642...86,696,408

G

G protein subunit gamma transducin 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GNGT2 mRNA

NCBI chr10:80,776,003...80,784,235
Ensembl chr10:81,277,423...81,280,970

G

glucosamine-phosphate N-acetyltransferase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GNPNAT1 mRNA

NCBI chr15:18,596,180...18,608,854
Ensembl chr15:21,076,130...21,088,423

G

G protein-coupled bile acid receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPBAR1 mRNA

NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:83,311,246...83,315,608

G

glypican 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPC4 mRNA

NCBI chr X:136,565,536...136,676,142
Ensembl chr X:136,565,591...136,676,057

G

G protein-coupled receptor 119

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of GPR119 mRNA

NCBI chr X:127,852,145...127,858,198
Ensembl chr X:132,730,027...132,736,080

G

G protein-coupled receptor 137B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR137B mRNA

NCBI chr17:92,987,792...93,026,003
Ensembl chr17:92,942,559...93,025,911

G

G protein-coupled receptor 149

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR149 mRNA

NCBI chr 2:146,909,710...146,981,924
Ensembl chr 2:149,059,336...149,130,785

G

G protein-coupled receptor 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR15 mRNA

NCBI chr11:41,898,300...41,899,646
Ensembl chr11:55,358,614...55,374,150

G

G protein-coupled receptor 152

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR152 mRNA

NCBI chr 1:201,435,878...201,438,373
Ensembl chr 1:210,865,338...210,867,833

G

G protein-coupled receptor 17

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR17 mRNA

NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,850,107...23,857,702

G

G protein-coupled receptor 176

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR176 mRNA

NCBI chr 3:105,236,794...105,337,664
Ensembl chr 3:125,690,751...125,791,172

G

G protein-coupled receptor 20

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR20 mRNA

NCBI chr 7:107,490,419...107,500,993
Ensembl chr 7:107,490,713...107,500,966

G

G protein-coupled receptor 27

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR27 mRNA

NCBI chr 4:133,884,894...133,886,027
Ensembl chr 4:133,883,234...133,904,093

G

G protein-coupled receptor 37-like 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR37L1 mRNA

NCBI chr13:46,598,574...46,605,421
Ensembl chr13:49,150,359...49,157,204

G

G protein-coupled receptor 39

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR39 mRNA

NCBI chr13:39,667,908...39,879,944
Ensembl chr13:39,667,909...39,880,902

G

G protein-coupled receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR4 mRNA

NCBI chr 1:78,865,376...78,877,126
Ensembl chr 1:87,993,430...88,006,254

G

G protein-coupled receptor 50

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR50 mRNA

NCBI chr X:149,368,900...149,373,486
Ensembl chr X:154,413,689...154,418,275

G

G protein-coupled receptor 68

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GPR68 mRNA

NCBI chr 6:125,865,205...125,895,674
Ensembl chr 6:125,864,942...125,895,674

G

G protein-coupled receptor 83

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR83 mRNA

NCBI chr 8:11,693,540...11,704,028
Ensembl chr 8:19,974,993...19,985,490

G

G protein-coupled receptor 85

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR85 mRNA

NCBI chr 4:42,100,138...42,109,584
Ensembl chr 4:43,060,777...43,075,794

G

G-protein coupled receptor 88

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPR88 mRNA

NCBI chr 2:204,191,443...204,199,576
Ensembl chr 2:206,868,585...206,884,945

G

G protein-coupled receptor, class C, group 5, member B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5B mRNA

NCBI chr 1:173,316,904...173,340,933
Ensembl chr 1:182,748,247...182,772,757

G

G protein-coupled receptor, class C, group 5, member D

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPRC5D mRNA

NCBI chr 4:167,943,523...167,955,616
Ensembl chr 4:169,674,846...169,686,965

G

glutathione peroxidase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX3 mRNA

NCBI chr10:39,529,335...39,537,406
Ensembl chr10:39,529,448...39,537,405

G

glutathione peroxidase 4

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased activity of GPX4 protein; sinpeinine A inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased activity of GPX4 protein]

NCBI chr 7:10,300,833...10,303,629
Ensembl chr 7:10,300,832...10,303,629

G

glutathione peroxidase 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX7 mRNA

NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:128,372,875...128,381,725

G

glutathione peroxidase 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GPX8 mRNA

NCBI chr 2:44,676,448...44,680,042
Ensembl chr 2:46,409,139...46,413,406

G

growth factor receptor bound protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRB2 mRNA

NCBI chr10:101,380,354...101,448,138
Ensembl chr10:101,380,356...101,448,138

G

growth factor receptor bound protein 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRB7 mRNA

NCBI chr10:83,936,538...83,949,344
Ensembl chr10:83,939,299...83,949,382

G

glutamate ionotropic receptor kainate type subunit 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIK4 mRNA

NCBI chr 8:42,903,043...43,331,990
Ensembl chr 8:51,802,058...52,102,063

G

glutamate ionotropic receptor NMDA type subunit 2B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRIN2B mRNA

NCBI chr 4:170,297,811...170,775,420
Ensembl chr 4:170,322,617...170,773,570

G

glutamate ionotropic receptor NMDA type subunit 2D

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRIN2D mRNA

NCBI chr 1:105,443,317...105,483,400
Ensembl chr 1:105,444,813...105,481,236

G

G protein-coupled receptor kinase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRK3 mRNA

NCBI chr12:49,285,228...49,395,803
Ensembl chr12:49,285,263...49,395,802

G

glutamate metabotropic receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GRM4 mRNA

NCBI chr20:5,484,172...5,572,821
Ensembl chr20:5,482,977...5,574,668

G

gastrin releasing peptide receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GRPR mRNA

NCBI chr X:30,998,425...31,038,442
Ensembl chr X:34,630,229...34,670,245

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

ISO

Azoxymethane results in increased phosphorylation of GSK3B protein
pterostilbene inhibits the reaction [Azoxymethane results in increased phosphorylation of GSK3B protein]

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

gelsolin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GSN mRNA

NCBI chr 3:38,982,605...39,035,849
Ensembl chr 3:38,982,671...39,035,850

G

glutathione-disulfide reductase

increases expression
multiple interactions

ISO

Azoxymethane results in increased expression of GSR mRNA
NFE2L2 protein promotes the reaction [pterostilbene promotes the reaction [Azoxymethane results in increased expression of GSR mRNA]]; NFE2L2 protein promotes the reaction [Resveratrol promotes the reaction [Azoxymethane results in increased expression of GSR mRNA]]; pterostilbene promotes the reaction [Azoxymethane results in increased expression of GSR mRNA]; Resveratrol promotes the reaction [Azoxymethane results in increased expression of GSR mRNA]

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:65,185,574...65,228,394

G

glutathione synthetase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSS mRNA

NCBI chr 3:144,047,849...144,078,197
Ensembl chr 3:164,508,005...164,538,306

G

glutathione S-transferase kappa 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTK1 mRNA

NCBI chr 4:71,118,979...71,123,298
Ensembl chr 4:72,085,531...72,089,927

G

glutathione S-transferase omega 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO1 mRNA

NCBI chr 1:246,721,089...246,731,228
Ensembl chr 1:256,662,531...256,676,167

G

glutathione S-transferase omega 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GSTO2 mRNA

NCBI chr 1:246,731,314...246,757,592
Ensembl chr 1:256,673,274...256,695,146

G

guanylate cyclase activator 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GUCA1A mRNA

NCBI chr 9:13,588,988...13,598,566
Ensembl chr 9:21,086,642...21,096,221

G

guanylate cyclase activator 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCA1B mRNA

NCBI chr 9:13,599,619...13,607,455
Ensembl chr 9:21,097,274...21,105,107

G

guanylate cyclase 2F

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of GUCY2F mRNA

NCBI chr X:105,710,356...105,808,183
Ensembl chr X:110,507,183...110,605,017

G

granzyme A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of GZMA mRNA

NCBI chr 2:44,740,569...44,752,502
Ensembl chr 2:46,473,763...46,485,696

G

H2A.X variant histone

increases expression

ISO

Azoxymethane results in increased expression of H2AX protein

NCBI chr 8:53,568,718...53,570,072
Ensembl chr 8:53,568,281...53,573,079

G

hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HADHB mRNA

NCBI chr 6:31,873,404...31,907,557
Ensembl chr 6:31,873,404...31,907,835

G

hyperpolarization activated cyclic nucleotide gated potassium and sodium channel 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN2 mRNA

NCBI chr 7:10,620,422...10,639,457
Ensembl chr 7:10,620,422...10,639,457

G

hyperpolarization-activated cyclic nucleotide-gated potassium channel 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN3 mRNA

NCBI chr 2:176,849,635...176,867,726
Ensembl chr 2:176,849,635...176,868,538

G

hyperpolarization activated cyclic nucleotide-gated potassium channel 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HCN4 mRNA

NCBI chr 8:68,118,062...68,155,482
Ensembl chr 8:68,118,062...68,155,495

G

hephaestin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HEPH mRNA

NCBI chr X:65,160,628...65,412,457
Ensembl chr X:65,305,773...65,412,453

G

hes family bHLH transcription factor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HES1 mRNA

NCBI chr11:84,210,632...84,213,045
Ensembl chr11:84,210,633...84,213,061

G

hexokinase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HK3 mRNA

NCBI chr17:9,596,950...9,614,847
Ensembl chr17:9,605,016...9,620,037

G

heme oxygenase 1

multiple interactions
increases expression

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HMOX1 mRNA; NFE2L2 protein promotes the reaction [pterostilbene promotes the reaction [Azoxymethane results in increased expression of HMOX1 mRNA]]; NFE2L2 protein promotes the reaction [Resveratrol promotes the reaction [Azoxymethane results in increased expression of HMOX1 mRNA]]; pterostilbene promotes the reaction [Azoxymethane results in increased expression of HMOX1 mRNA]; pterostilbene promotes the reaction [Azoxymethane results in increased expression of HMOX1 protein]; Resveratrol promotes the reaction [Azoxymethane results in increased expression of HMOX1 mRNA]; Resveratrol promotes the reaction [Azoxymethane results in increased expression of HMOX1 protein]
Azoxymethane results in increased expression of HMOX1 mRNA; Azoxymethane results in increased expression of HMOX1 protein

PMID:21355597 PMID:29950665

NCBI chr19:13,452,365...13,479,823
Ensembl chr19:13,472,884...13,479,818

G

HNF1 homeobox A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1A mRNA

NCBI chr12:47,299,171...47,333,457
Ensembl chr12:47,306,245...47,332,755

G

HNF1 homeobox B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF1B mRNA

NCBI chr10:69,233,377...69,287,360
Ensembl chr10:69,233,131...69,287,361

G

hepatocyte nuclear factor 4, alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4A mRNA

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:172,606,220...172,667,758

G

hepatocyte nuclear factor 4, gamma

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HNF4G mRNA

NCBI chr 2:97,885,773...98,036,650
Ensembl chr 2:99,792,942...99,943,811

G

15-hydroxyprostaglandin dehydrogenase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HPGD mRNA

NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831

G

HRas proto-oncogene, GTPase

increases activity
multiple interactions

EXP

Azoxymethane results in increased activity of HRAS protein
Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased activity of HRAS protein]

NCBI chr 1:205,712,625...205,729,406
Ensembl chr 1:205,725,975...205,729,590

G

histamine receptor H3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HRH3 mRNA

NCBI chr 3:167,191,551...167,196,642
Ensembl chr 3:187,569,175...187,574,259

G

hydroxysteroid 11-beta dehydrogenase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:107,257,239...107,327,432

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD11B2 mRNA

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:50,307,569...50,312,812

G

hydroxysteroid (17-beta) dehydrogenase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSD17B1 mRNA

NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,510,011...86,512,210

G

hydroxysteroid (17-beta) dehydrogenase 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HSD17B6 mRNA

NCBI chr 7:422,466...442,008
Ensembl chr 7:831,421...850,873

G

heparan sulfate proteoglycan 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HSPG2 mRNA

NCBI chr 5:149,677,437...149,778,594
Ensembl chr 5:154,960,846...155,061,971

G

5-hydroxytryptamine receptor 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR1B mRNA

NCBI chr 8:82,513,572...82,534,670
Ensembl chr 8:91,052,432...91,418,583

G

5-hydroxytryptamine receptor 1D

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of HTR1D mRNA

NCBI chr 5:148,656,252...148,676,532
Ensembl chr 5:153,939,516...153,960,012

G

5-hydroxytryptamine receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of HTR4 mRNA

NCBI chr18:55,765,981...55,949,921
Ensembl chr18:58,036,277...58,219,622

G

5-hydroxytryptamine receptor 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of HTR7 mRNA

NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:243,049,081...243,173,230

G

intercellular adhesion molecule 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM1 mRNA

NCBI chr 8:27,829,688...27,841,618
Ensembl chr 8:27,829,161...27,841,617

G

intercellular adhesion molecule 4, Landsteiner-Wiener blood group

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICAM4 mRNA

NCBI chr 8:27,842,255...27,843,351
Ensembl chr 8:27,842,255...27,844,371

G

inducible T-cell co-stimulator ligand

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ICOSL mRNA

NCBI chr20:10,600,420...10,610,718
Ensembl chr20:10,600,078...10,610,365

G

interferon, alpha 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNA5 mRNA

NCBI chr 5:103,097,356...103,097,925
Ensembl chr 5:108,143,240...108,143,809

G

interferon alpha and beta receptor subunit 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNAR2 mRNA

NCBI chr11:30,613,576...30,645,958
Ensembl chr11:44,099,753...44,131,937

G

interferon gamma

increases expression
multiple interactions

ISO

Azoxymethane results in increased expression of IFNG protein
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNG protein; Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IFNG protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFNG protein]

PMID:20431929 PMID:25026504 PMID:34273909

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interferon kappa

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IFNK mRNA

NCBI chr 5:49,732,073...49,734,281
Ensembl chr 5:54,528,304...54,530,511

G

insulin-like growth factor 1

multiple interactions
affects expression

EXP
ISO

[Plant Extracts co-treated with Azoxymethane] results in decreased expression of IGF1 mRNA; [Plant Extracts co-treated with Azoxymethane] results in decreased expression of IGF1 protein
Azoxymethane affects the expression of IGF1 mRNA
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IGF1 protein; [Sodium Glutamate co-treated with Azoxymethane] affects the expression of IGF1 mRNA

PMID:19931517 PMID:22223845 PMID:23996930

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

insulin-like growth factor 1 receptor

affects expression
multiple interactions

ISO
EXP

Azoxymethane affects the expression of IGF1R mRNA
Sodium Glutamate affects the reaction [Azoxymethane affects the expression of IGF1R mRNA]
[Plant Extracts co-treated with Azoxymethane] results in decreased expression of IGF1R mRNA

PMID:22223845 PMID:23996930

NCBI chr 1:130,959,787...131,248,664
Ensembl chr 1:130,959,997...131,248,664

G

insulin-like growth factor 2

affects expression
multiple interactions

ISO

Azoxymethane affects the expression of IGF2 mRNA
[Sodium Glutamate co-treated with Azoxymethane] affects the expression of IGF2 mRNA

NCBI chr 1:207,243,873...207,261,263
Ensembl chr 1:207,243,873...207,260,667

G

insulin-like growth factor binding protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP2 mRNA

NCBI chr 9:81,864,811...81,892,179
Ensembl chr 9:81,864,783...81,892,171

G

insulin-like growth factor binding protein 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP4 mRNA

NCBI chr10:83,995,253...84,007,272
Ensembl chr10:84,485,775...84,503,473

G

insulin-like growth factor binding protein 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IGFBP6 mRNA

NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:135,154,685...135,159,795

G

Indian hedgehog signaling molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IHH mRNA

NCBI chr 9:76,504,315...76,510,532
Ensembl chr 9:83,952,986...83,959,203

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IKBKB mRNA

NCBI chr16:76,021,968...76,075,717
Ensembl chr16:76,022,008...76,081,911

G

interleukin 10

multiple interactions
decreases expression
increases expression

EXP
ISO

pinostrobin inhibits the reaction [Azoxymethane results in decreased expression of IL10 protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein; Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IL10 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL10 protein]

PMID:20431929 PMID:25026504 PMID:38078205

NCBI chr13:45,024,921...45,029,586
Ensembl chr13:45,025,087...45,029,580

G

interleukin 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11 mRNA

NCBI chr 1:78,098,622...78,104,915
Ensembl chr 1:78,096,930...78,104,915

G

interleukin 11 receptor subunit alpha 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL11RA1 mRNA

NCBI chr 5:56,931,824...56,941,408
Ensembl chr 5:61,727,931...61,737,264

G

interleukin 13

increases expression

ISO

Azoxymethane results in increased expression of IL13 protein

NCBI chr10:38,290,926...38,293,483
Ensembl chr10:38,290,926...38,293,483

G

interleukin 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL15 mRNA

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:42,545,346...42,611,348

G

interleukin 17A

increases expression
multiple interactions

ISO

Azoxymethane results in increased expression of IL17A protein
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL17A mRNA; Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IL17A protein]

PMID:20431929 PMID:29950665

NCBI chr 9:30,640,844...30,644,331
Ensembl chr 9:30,640,844...30,644,331

G

interleukin 18

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL18 mRNA

NCBI chr 8:59,802,072...59,829,275
Ensembl chr 8:59,809,592...59,831,286

G

interleukin 18 receptor accessory protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL18RAP mRNA

NCBI chr 9:50,263,723...50,296,583
Ensembl chr 9:50,263,733...50,296,583

G

interleukin 19

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL19 mRNA

NCBI chr13:44,949,989...44,958,714
Ensembl chr13:44,949,989...44,958,714

G

interleukin 1 alpha

multiple interactions
increases expression

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1A protein
Azoxymethane results in increased expression of IL1A protein

PMID:20431929 PMID:34273909

NCBI chr 3:136,979,804...136,990,236
Ensembl chr 3:136,979,805...136,998,013

G

interleukin 1 beta

increases expression
multiple interactions

EXP
ISO

Azoxymethane results in increased expression of IL1B mRNA
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1B mRNA; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL1B protein]
Azoxymethane results in increased expression of IL1B protein
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein; Aspirin inhibits the reaction [Azoxymethane results in increased expression of IL1B mRNA]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1B protein]

PMID:19028472 PMID:20043115 PMID:20431929 PMID:22334590 PMID:29950665 More...

NCBI chr 3:137,030,200...137,036,581
Ensembl chr 3:137,030,205...137,036,601

G

interleukin 1 receptor type 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:50,000,566...50,076,579

G

interleukin 1 receptor type 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL1R2 mRNA

NCBI chr 9:49,879,928...49,920,374
Ensembl chr 9:49,877,266...49,920,374

G

interleukin 1 receptor antagonist

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL1RN protein]

NCBI chr 3:27,509,836...27,525,738
Ensembl chr 3:27,509,798...27,525,732

G

interleukin 2

increases expression

ISO

Azoxymethane results in increased expression of IL2 protein

NCBI chr 2:121,932,968...121,937,672
Ensembl chr 2:121,932,968...121,937,672

G

interleukin 20 receptor subunit alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RA mRNA

NCBI chr 1:14,424,215...14,494,226
Ensembl chr 1:16,243,801...16,313,221

G

interleukin 20 receptor subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL20RB mRNA

NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:109,854,012...109,889,363

G

interleukin 22 receptor subunit alpha 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL22RA1 mRNA

NCBI chr 5:147,961,496...147,986,296
Ensembl chr 5:153,245,002...153,271,683

G

interleukin 3

increases expression

ISO

Azoxymethane results in increased expression of IL3 protein

NCBI chr10:38,906,460...38,908,810
Ensembl chr10:38,906,460...38,908,810

G

interleukin 3 receptor subunit alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL3RA mRNA

NCBI chr12:16,318,081...16,323,781
Ensembl chr12:21,431,848...21,437,250

G

interleukin 4

multiple interactions
affects expression

EXP

[Raloxifene Hydrochloride co-treated with Bexarotene] affects the reaction [Azoxymethane affects the expression of IL4 mRNA]; Bexarotene affects the reaction [Azoxymethane affects the expression of IL4 mRNA]

NCBI chr10:38,272,003...38,277,549
Ensembl chr10:38,272,003...38,277,549

G

interleukin 4 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL4RA mRNA

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636

G

interleukin 5

increases expression
multiple interactions

ISO

Azoxymethane results in increased expression of IL5 protein
Acetylcysteine inhibits the reaction [Azoxymethane results in increased expression of IL5 protein]

NCBI chr10:38,375,132...38,378,003
Ensembl chr10:38,375,132...38,378,003

G

interleukin 6

increases expression
multiple interactions
affects expression

ISO
EXP

Azoxymethane results in increased expression of IL6 protein
pinostrobin inhibits the reaction [Azoxymethane results in increased expression of IL6 protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of IL6 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of IL6 protein]
Azoxymethane affects the expression of IL6 mRNA

PMID:20431929 PMID:22334590 PMID:24080207 PMID:25026504 PMID:34273909 More...

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interleukin 6 cytokine family signal transducer

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL6ST mRNA

NCBI chr 2:45,798,872...45,839,501
Ensembl chr 2:45,799,380...45,843,182

G

interleukin 7 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IL7R mRNA

NCBI chr 2:60,179,561...60,204,937
Ensembl chr 2:60,181,382...60,211,027

G

interleukin 9

increases expression

ISO

Azoxymethane results in increased expression of IL9 protein

NCBI chr17:8,111,772...8,114,895
Ensembl chr17:8,117,028...8,120,151

G

inhibin subunit beta A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBA mRNA

NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508

G

inhibin subunit beta B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INHBB mRNA

NCBI chr13:33,083,671...33,089,373
Ensembl chr13:33,083,671...33,089,609

G

inositol polyphosphate-5-phosphatase D

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INPP5D mRNA

NCBI chr 9:95,735,533...95,840,584
Ensembl chr 9:95,735,530...95,840,589

G

insulin 1

multiple interactions

ISO

Azoxymethane inhibits the reaction [Sodium Glutamate results in increased expression of INS1 protein]

NCBI chr 1:261,186,119...261,186,686
Ensembl chr 1:261,186,119...261,186,682

G

insulin like 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of INSL5 mRNA

NCBI chr 5:117,773,104...117,777,376

G

interleukin-1 receptor-associated kinase 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK1 protein

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:156,920,081...156,929,825

G

interleukin-1 receptor-associated kinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRAK2 mRNA

NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:148,341,719...148,398,210

G

interleukin-1 receptor-associated kinase 4

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of IRAK4 protein

NCBI chr 7:125,682,502...125,708,294
Ensembl chr 7:127,561,717...127,597,109

G

insulin receptor substrate 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRS1 mRNA

NCBI chr 9:91,001,137...91,053,959
Ensembl chr 9:90,993,519...91,054,538

G

iroquois homeobox 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IRX6 mRNA

NCBI chr19:14,330,440...14,336,403
Ensembl chr19:30,503,419...30,509,382

G

integrin subunit alpha 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGA10 mRNA

NCBI chr 2:184,182,869...184,202,172
Ensembl chr 2:186,871,711...186,891,012

G

integrin subunit alpha 2b

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA2B mRNA

NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,908,697...87,925,833

G

integrin subunit alpha 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA4 mRNA

NCBI chr 3:84,569,487...84,646,276
Ensembl chr 3:84,560,369...84,641,039

G

integrin subunit alpha 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA5 mRNA

NCBI chr 7:134,478,963...134,502,837
Ensembl chr 7:136,358,097...136,381,305

G

integrin subunit alpha 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGA6 mRNA

NCBI chr 3:77,012,168...77,097,076
Ensembl chr 3:77,017,766...77,097,076

G

integrin subunit beta 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB1 mRNA

NCBI chr19:73,602,277...73,650,271
Ensembl chr19:73,602,126...73,650,269

G

integrin subunit beta 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB2 mRNA

NCBI chr20:11,061,009...11,097,242
Ensembl chr20:11,058,492...11,097,182

G

integrin subunit beta 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB3 mRNA

NCBI chr10:90,009,927...90,067,787
Ensembl chr10:90,009,900...90,067,800

G

integrin subunit beta 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITGB6 mRNA

NCBI chr 3:65,454,964...65,579,179
Ensembl chr 3:65,456,713...65,530,333

G

integrin subunit beta 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ITGB8 mRNA

NCBI chr 6:140,125,002...140,208,261
Ensembl chr 6:146,165,484...146,351,245

G

inositol-trisphosphate 3-kinase A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPKA mRNA

NCBI chr 3:106,726,036...106,734,601
Ensembl chr 3:127,179,808...127,188,414

G

inositol 1,4,5-trisphosphate receptor, type 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ITPR3 mRNA

NCBI chr20:5,136,968...5,202,339
Ensembl chr20:5,118,834...5,204,184

G

junctional adhesion molecule 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM2 mRNA

NCBI chr11:23,830,820...23,880,071
Ensembl chr11:37,317,511...37,367,510

G

junctional adhesion molecule 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAM3 mRNA

NCBI chr 8:33,767,606...33,828,451
Ensembl chr 8:33,767,607...33,828,623

G

junction adhesion molecule like

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of JAML mRNA

NCBI chr 8:45,384,836...45,415,459
Ensembl chr 8:54,281,644...54,313,500

G

potassium voltage-gated channel subfamily A regulatory beta subunit 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNAB1 mRNA

NCBI chr 2:149,137,025...149,603,540
Ensembl chr 2:151,446,947...151,913,636

G

potassium voltage-gated channel subfamily E regulatory subunit 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNE3 mRNA

NCBI chr 1:163,936,035...163,942,998
Ensembl chr 1:163,935,991...163,950,162

G

potassium voltage-gated channel subfamily H member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNH2 mRNA

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:11,692,980...11,751,421

G

potassium inwardly-rectifying channel, subfamily J, member 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNJ9 mRNA

NCBI chr13:84,780,826...84,787,928
Ensembl chr13:87,312,378...87,320,293

G

potassium two pore domain channel subfamily K member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KCNK4 mRNA

NCBI chr 1:213,547,577...213,558,706
Ensembl chr 1:213,547,577...213,555,861

G

potassium two pore domain channel subfamily K member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KCNK5 mRNA

NCBI chr15:4,122,442...4,164,718
Ensembl chr15:4,171,610...4,213,897

G

KiSS-1 metastasis-suppressor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KISS1 mRNA

NCBI chr13:47,327,159...47,332,759
Ensembl chr13:47,327,004...47,332,906

G

KIT proto-oncogene receptor tyrosine kinase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KIT mRNA

NCBI chr14:32,901,615...32,978,895
Ensembl chr14:32,903,033...32,978,812

G

KIT ligand

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KITL mRNA

NCBI chr 7:36,782,621...36,863,796
Ensembl chr 7:36,782,638...36,863,793

G

klotho beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of KLB mRNA

NCBI chr14:42,899,050...42,950,788
Ensembl chr14:43,253,255...43,304,515

G

kallikrein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1 mRNA

NCBI chr 1:94,642,644...94,646,760
Ensembl chr 1:103,779,164...103,783,270

G

kallikrein 1-related peptidase B3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KLK1B3 mRNA

NCBI chr 1:94,709,105...94,713,308
Ensembl chr 1:103,845,603...103,849,855

G

KRAS proto-oncogene, GTPase

multiple interactions
increases mutagenesis

ISO
EXP

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of KRAS mRNA
Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased mutagenesis of KRAS gene]

PMID:12839936 PMID:21370285 PMID:29950665

NCBI chr 4:179,916,255...179,949,613
Ensembl chr 4:179,919,802...179,949,320

G

L1 cell adhesion molecule

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of L1CAM mRNA

NCBI chr X:156,748,597...156,775,116
Ensembl chr X:156,748,597...156,775,077

G

laminin subunit alpha 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMA5 mRNA

NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:187,647,904...187,696,173

G

laminin subunit beta 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMB2 mRNA

NCBI chr 8:118,056,899...118,069,090
Ensembl chr 8:118,056,935...118,069,090

G

laminin subunit beta 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LAMB3 mRNA

NCBI chr13:104,833,810...104,875,405
Ensembl chr13:107,322,526...107,404,081

G

laminin subunit gamma 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAMC1 mRNA

NCBI chr13:67,924,872...68,051,986
Ensembl chr13:67,924,872...68,051,986

G

linker for activation of T cells family, member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LAT2 mRNA

NCBI chr12:22,104,173...22,118,294
Ensembl chr12:27,740,654...27,755,843

G

lipocalin 2

decreases expression
multiple interactions

EXP

Azoxymethane results in decreased expression of LCN2 mRNA
Aspirin inhibits the reaction [Azoxymethane results in decreased expression of LCN2 mRNA]

NCBI chr 3:36,078,432...36,081,851
Ensembl chr 3:36,078,436...36,081,842

G

lactate dehydrogenase A-like 6B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LDHAL6B mRNA

NCBI chr 1:45,997,845...45,999,268
Ensembl chr 1:48,403,012...48,404,851

G

lactate dehydrogenase B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LDHB mRNA

NCBI chr 4:175,428,382...175,446,403
Ensembl chr 4:177,159,392...177,177,408

G

lymphoid enhancer binding factor 1

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LEF1 protein]

NCBI chr 2:222,340,541...222,453,931
Ensembl chr 2:222,340,704...222,453,929

G

leptin

increases expression
multiple interactions

ISO

Azoxymethane results in increased expression of LEP protein
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LEP protein; Quercetin inhibits the reaction [Azoxymethane results in increased expression of LEP protein]

PMID:19914226 PMID:19931517

NCBI chr 4:58,626,529...58,640,663
Ensembl chr 4:58,626,523...58,640,661

G

leucine-rich repeat-containing G protein-coupled receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LGR4 mRNA

NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:116,901,968...117,004,153

G

leucine-rich repeat-containing G protein-coupled receptor 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LGR6 mRNA

NCBI chr13:46,424,382...46,544,074
Ensembl chr13:48,976,193...49,095,857

G

luteinizing hormone/choriogonadotropin receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of LHCGR mRNA

NCBI chr 6:5,661,871...5,728,109
Ensembl chr 6:11,415,415...11,478,061

G

LIM domain kinase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LIMK1 mRNA

NCBI chr12:27,663,177...27,697,085
Ensembl chr12:27,663,018...27,697,209

G

lysyl oxidase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOX mRNA

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:48,165,688...48,239,810

G

lysyl oxidase-like 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LOXL1 mRNA

NCBI chr 8:58,691,763...58,716,365
Ensembl chr 8:67,587,636...67,612,224

G

lysophosphatidic acid receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR2 mRNA

NCBI chr16:19,592,067...19,599,998
Ensembl chr16:19,625,983...19,633,905

G

lysophosphatidic acid receptor 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LPAR3 mRNA

NCBI chr 2:235,125,234...235,193,916
Ensembl chr 2:237,787,766...237,854,197

G

lysophosphatidic acid receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LPAR4 mRNA

NCBI chr X:72,033,486...72,046,978
Ensembl chr X:76,106,071...76,119,808

G

LDL receptor related protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of LRP1 mRNA

NCBI chr 7:65,265,639...65,346,196
Ensembl chr 7:65,265,639...65,346,196

G

LDL receptor related protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LRP2 mRNA

NCBI chr 3:74,597,148...74,754,535
Ensembl chr 3:74,597,148...74,754,535

G

LDL receptor related protein 5

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of LRP5 mRNA]

NCBI chr 1:210,243,499...210,346,886
Ensembl chr 1:210,243,502...210,346,822

G

leukotriene B4 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTB4R1 mRNA

NCBI chr15:33,233,120...33,235,636
Ensembl chr15:33,232,820...33,235,637

G

latent transforming growth factor beta binding protein 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP3 mRNA

NCBI chr 1:203,029,412...203,045,975
Ensembl chr 1:212,459,185...212,475,302

G

latent transforming growth factor beta binding protein 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of LTBP4 mRNA

NCBI chr 1:91,727,769...91,759,822
Ensembl chr 1:91,727,769...91,760,006

G

myelin-associated glycoprotein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAG mRNA

NCBI chr 1:86,148,227...86,163,726
Ensembl chr 1:95,275,635...95,291,060

G

monoamine oxidase A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MAOA mRNA

NCBI chr X:8,615,239...8,681,372
Ensembl chr X:8,615,239...8,682,631

G

mitogen activated protein kinase 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK1 protein

NCBI chr11:97,462,025...97,529,193
Ensembl chr11:97,462,025...97,527,825

G

mitogen activated protein kinase 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MAPK10 mRNA

NCBI chr14:6,802,247...7,094,103
Ensembl chr14:6,802,295...7,094,100

G

mitogen activated protein kinase 3

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of MAPK3 protein

NCBI chr 1:190,797,189...190,803,411
Ensembl chr 1:190,797,185...190,803,411

G

MBL associated serine protease 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MASP1 mRNA

NCBI chr11:90,839,081...90,909,922
Ensembl chr11:90,839,061...90,917,470

G

matrilin 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MATN4 mRNA

NCBI chr 3:153,120,605...153,135,628
Ensembl chr 3:173,539,966...173,554,984

G

melanocortin 4 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MC4R mRNA

NCBI chr18:60,419,832...60,421,719

G

midkine

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MDK mRNA

NCBI chr 3:98,356,789...98,358,960
Ensembl chr 3:98,356,789...98,358,743

G

meprin A subunit alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1A mRNA

NCBI chr 9:17,474,634...17,504,147
Ensembl chr 9:24,971,886...25,001,414

G

meprin A subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MEP1B mRNA

NCBI chr18:12,366,126...12,392,840
Ensembl chr18:12,641,041...12,667,755

G

microfibril associated protein 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP4 mRNA

NCBI chr10:46,167,158...46,170,176
Ensembl chr10:46,655,722...46,669,740

G

microfibril associated protein 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MFAP5 mRNA

NCBI chr 4:155,727,925...155,750,458
Ensembl chr 4:157,395,597...157,422,448

G

matrix Gla protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MGP mRNA

NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:171,497,471...171,500,859

G

microsomal glutathione S-transferase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST2 mRNA

NCBI chr 2:135,679,524...135,715,828
Ensembl chr 2:137,836,140...137,866,661

G

microsomal glutathione S-transferase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MGST3 mRNA

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:82,059,480...82,080,575

G

myo-inositol oxygenase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MIOX mRNA

NCBI chr 7:120,405,031...120,407,529
Ensembl chr 7:122,284,660...122,287,157

G

microRNA 126a

multiple interactions

EXP

[Plant Extracts co-treated with Azoxymethane] results in increased expression of MIR126 mRNA

NCBI chr 3:9,415,063...9,415,180

G

marker of proliferation Ki-67

multiple interactions
increases expression

ISO
EXP

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein; berberrubine inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MKI67 protein]; sinpeinine A inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MKI67 protein]
Azoxymethane results in increased expression of MKI67 protein

PMID:19028472 PMID:34273909 PMID:37871880 PMID:38563870 PMID:39551424

NCBI chr 1:199,926,150...199,952,847
Ensembl chr 1:199,926,150...199,952,593

G

membrane metallo-endopeptidase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MME mRNA

NCBI chr 2:149,806,826...149,957,381
Ensembl chr 2:149,872,291...149,953,463

G

matrix metallopeptidase 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP10 mRNA

NCBI chr 8:4,689,840...4,697,748
Ensembl chr 8:12,974,707...12,982,613

G

matrix metallopeptidase 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP12 mRNA

NCBI chr 8:4,581,785...4,591,687
Ensembl chr 8:12,866,641...12,884,478

G

matrix metallopeptidase 13

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:12,782,813...12,793,105

G

matrix metallopeptidase 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP14 mRNA

NCBI chr15:31,857,824...31,867,049
Ensembl chr15:31,857,546...31,869,893

G

matrix metallopeptidase 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMP15 mRNA

NCBI chr19:9,663,449...9,684,943
Ensembl chr19:9,669,506...9,691,000

G

matrix metallopeptidase 19

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP19 mRNA

NCBI chr 7:1,221,229...1,229,555
Ensembl chr 7:1,805,860...1,814,863

G

matrix metallopeptidase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP2 mRNA

NCBI chr19:30,327,643...30,355,856
Ensembl chr19:30,327,643...30,355,856

G

matrix metallopeptidase 23

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP23 mRNA

NCBI chr 5:166,239,643...166,242,734
Ensembl chr 5:171,520,494...171,524,695

G

matrix metallopeptidase 28

multiple interactions
increases activity

ISO

pterostilbene inhibits the reaction [Azoxymethane results in increased activity of MMP26 protein]

NCBI chr10:68,738,651...68,762,377
Ensembl chr10:68,738,651...68,824,884

G

matrix metallopeptidase 3

multiple interactions
increases expression

EXP

Aspirin inhibits the reaction [Azoxymethane results in increased expression of MMP3 mRNA]

NCBI chr 8:12,925,267...12,938,828
Ensembl chr 8:12,925,280...12,938,826

G

matrix metallopeptidase 7

multiple interactions
increases expression
increases activity

ISO
EXP

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MMP7 mRNA]; pterostilbene inhibits the reaction [Azoxymethane results in increased activity of MMP7 protein]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of MMP7 mRNA]
Aspirin inhibits the reaction [Azoxymethane results in increased expression of MMP7 mRNA]

PMID:20043115 PMID:20681671 PMID:31715269

NCBI chr 8:13,133,043...13,140,761
Ensembl chr 8:13,133,043...13,140,755

G

matrix metallopeptidase 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP8 mRNA

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:13,008,890...13,018,729

G

matrix metallopeptidase 9

multiple interactions
affects expression

ISO
EXP

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MMP9 mRNA
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Glucose affects the reaction [Azoxymethane affects the expression of MMP9 protein]; Linoleic Acid affects the reaction [Azoxymethane affects the expression of MMP9 protein]

PMID:22467055 PMID:29950665

NCBI chr 3:174,103,474...174,111,434
Ensembl chr 3:174,084,123...174,111,442

G

methylmalonyl-CoA mutase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MMUT mRNA

NCBI chr 9:19,928,720...19,956,985
Ensembl chr 9:27,425,935...27,454,342

G

myeloid cell nuclear differentiation antigen

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of IFI204 mRNA

NCBI chr13:86,017,888...86,035,556
Ensembl chr13:88,550,228...88,566,537

G

mannose phosphate isomerase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MPI mRNA

NCBI chr 8:57,947,883...57,956,205
Ensembl chr 8:66,844,116...66,852,016

G

mannose receptor, C type 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MRC1 protein]

NCBI chr17:77,249,187...77,330,857
Ensembl chr17:82,157,705...82,239,410

G

moesin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MSN mRNA

NCBI chr X:65,005,546...65,073,512
Ensembl chr X:65,005,458...65,075,129

G

metallothionein 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MT1 mRNA

NCBI chr19:10,831,959...10,832,975
Ensembl chr17:79,695,809...79,696,200
Ensembl chr X:79,695,809...79,696,200
Ensembl chr19:79,695,809...79,696,200

G

melatonin receptor 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1A mRNA

NCBI chr16:47,144,461...47,163,919
Ensembl chr16:53,876,964...53,896,421

G

melatonin receptor 1B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MTNR1B mRNA

NCBI chr 8:12,638,219...12,652,737
Ensembl chr 8:20,919,593...20,934,109

G

mechanistic target of rapamycin kinase

multiple interactions

EXP

[Plant Extracts co-treated with Azoxymethane] results in decreased expression of MTOR mRNA; [Plant Extracts co-treated with Azoxymethane] results in decreased phosphorylation of MTOR protein

NCBI chr 5:164,167,985...164,277,438
Ensembl chr 5:164,167,928...164,277,435

G

mucin 13, cell surface associated

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC13 mRNA

NCBI chr11:66,957,208...66,980,264
Ensembl chr11:80,465,737...80,485,474

G

mucin 4, cell surface associated

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of MUC4 mRNA

NCBI chr11:81,513,321...81,575,200

G

muscle associated receptor tyrosine kinase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MUSK mRNA

NCBI chr 5:77,853,560...77,967,653
Ensembl chr 5:77,853,736...77,964,338

G

myosin binding protein C1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC1 mRNA

NCBI chr 7:22,930,350...23,015,981
Ensembl chr 7:24,817,561...24,903,544

G

myosin binding protein C2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC2 mRNA

NCBI chr 1:94,994,121...95,017,584
Ensembl chr 1:104,131,323...104,154,101

G

myosin binding protein C3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYBPC3 mRNA

NCBI chr 3:77,095,165...77,113,406
Ensembl chr 3:97,551,061...97,569,216

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
increases expression

EXP
ISO

Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Calcium Chloride inhibits the reaction [Azoxymethane results in increased expression of MYC protein]; Piroxicam inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Piroxicam inhibits the reaction [Azoxymethane results in increased expression of MYC protein]; Sulindac inhibits the reaction [Azoxymethane results in increased expression of MYC mRNA]; Sulindac inhibits the reaction [Azoxymethane results in increased expression of MYC protein]; xanthohumol inhibits the reaction [Azoxymethane results in increased expression of MYC protein]
[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC mRNA]; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of MYC protein]
Azoxymethane results in increased expression of MYC mRNA; Azoxymethane results in increased expression of MYC protein

PMID:12189186 PMID:31714664 PMID:31715269

NCBI chr 7:95,483,105...95,488,031
Ensembl chr 7:95,483,105...95,488,028

G

myosin heavy chain 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYH8 mRNA

NCBI chr10:51,963,510...51,993,103
Ensembl chr10:52,462,509...52,492,105

G

myosin, light chain 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL1 mRNA

NCBI chr 9:68,437,514...68,458,256
Ensembl chr 9:75,887,227...75,907,971

G

myosin light chain 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYL3 mRNA

NCBI chr 8:110,738,669...110,744,814
Ensembl chr 8:119,616,868...119,623,216

G

myosin light chain kinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYLK2 mRNA

NCBI chr 3:141,376,450...141,388,357
Ensembl chr 3:161,836,740...161,848,607

G

myosin VIIA

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MYO7A mRNA

NCBI chr 1:161,755,110...161,825,397
Ensembl chr 1:161,755,110...161,825,365

G

sodium leak channel, non-selective

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of NALCN mRNA

NCBI chr15:100,398,583...100,741,243
Ensembl chr15:106,805,209...107,147,858

G

N-acetylneuraminate synthase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NANS mRNA

NCBI chr 5:60,780,441...60,797,583
Ensembl chr 5:65,576,015...65,610,547

G

N-acetyltransferase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NAT2 mRNA

NCBI chr16:26,974,874...27,005,191
Ensembl chr16:26,974,601...26,976,304

G

neurocan

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCAN mRNA

NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,335,907...19,362,371

G

neutral cholesterol ester hydrolase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCEH1 mRNA

NCBI chr 2:110,074,985...110,135,592
Ensembl chr 2:112,003,502...112,064,272

G

NCK interacting protein with SH3 domain

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NCKIPSD mRNA

NCBI chr 8:109,511,484...109,522,622
Ensembl chr 8:118,390,159...118,401,118

G

nuclear receptor co-repressor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NCOR2 mRNA

NCBI chr12:37,127,736...37,289,612
Ensembl chr12:37,127,686...37,289,612

G

nebulin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NEB mRNA

NCBI chr 3:36,613,677...36,811,618
Ensembl chr 3:57,022,822...57,220,709

G

neuronal differentiation 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NEUROD1 mRNA

NCBI chr 3:84,766,483...84,770,454
Ensembl chr 3:84,764,725...84,770,810

G

NFE2 like bZIP transcription factor 2

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] affects the localization of NFE2L2 protein; NFE2L2 protein affects the susceptibility to [Azoxymethane co-treated with Dextran Sulfate]; NFE2L2 protein promotes the reaction [pterostilbene promotes the reaction [Azoxymethane results in increased expression of GSR mRNA]]; NFE2L2 protein promotes the reaction [pterostilbene promotes the reaction [Azoxymethane results in increased expression of HMOX1 mRNA]]; NFE2L2 protein promotes the reaction [Resveratrol promotes the reaction [Azoxymethane results in increased expression of GSR mRNA]]; NFE2L2 protein promotes the reaction [Resveratrol promotes the reaction [Azoxymethane results in increased expression of HMOX1 mRNA]]; NFE2L2 results in decreased susceptibility to [Dextran Sulfate co-treated with Azoxymethane]; sinpeinine A inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of NFE2L2 protein]

PMID:21355597 PMID:23056183 PMID:30844440 PMID:39551424

NCBI chr 3:81,001,529...81,031,165
Ensembl chr 3:81,001,529...81,029,090

G

nuclear factor kappa B subunit 1

multiple interactions

EXP

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:226,689,745...226,783,088

G

nidogen 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NID2 mRNA

NCBI chr15:4,458,082...4,513,808
Ensembl chr15:4,506,756...4,562,949

G

NKD inhibitor of WNT signaling pathway 1

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NKD1 mRNA]

NCBI chr19:18,476,344...18,549,380

G

NK2 homeobox 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NKX2-2 mRNA

NCBI chr 3:134,619,701...134,630,282
Ensembl chr 3:155,073,250...155,083,249

G

neuroligin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN1 mRNA

NCBI chr 2:110,184,987...111,110,316
Ensembl chr 2:110,186,573...110,909,984

G

neuroligin 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLGN3 mRNA

NCBI chr X:70,469,251...70,497,380
Ensembl chr X:70,469,457...70,497,379

G

NLR family, pyrin domain containing 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NLRP1A mRNA

NCBI chr10:55,778,560...55,833,639
Ensembl chr10:56,277,134...56,323,880

G

neuromedin B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NMB mRNA

NCBI chr 1:134,869,446...134,875,507
Ensembl chr 1:144,278,453...144,281,422

G

neuromedin U receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NMUR2 mRNA

NCBI chr10:40,166,223...40,182,078
Ensembl chr10:40,645,101...40,682,679

G

nitric oxide synthase 2

affects expression
multiple interactions
increases expression

EXP
ISO

Azoxymethane affects the expression of NOS2 protein
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS2 protein]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of NOS2 mRNA]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of NOS2 protein]; Resveratrol inhibits the reaction [Azoxymethane results in increased expression of NOS2 mRNA]; Resveratrol inhibits the reaction [Azoxymethane results in increased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NOS2 mRNA]
[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of NOS2 protein]; [Plant Extracts co-treated with Azoxymethane] results in decreased expression of NOS2 mRNA; [Plant Extracts co-treated with Azoxymethane] results in decreased expression of NOS2 protein; Linoleic Acid affects the reaction [Azoxymethane affects the expression of NOS2 protein]; Ro 24-5531 inhibits the reaction [Azoxymethane results in increased expression of NOS2 protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of NOS2 protein]; xanthohumol inhibits the reaction [Azoxymethane results in increased expression of NOS2 mRNA]
Azoxymethane results in increased expression of NOS2 mRNA; Azoxymethane results in increased expression of NOS2 protein

PMID:12496057 PMID:17438113 PMID:19056647 PMID:20681671 PMID:21355597 More...

NCBI chr10:64,313,335...64,349,221
Ensembl chr10:64,313,335...64,401,880

G

nitric oxide synthase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NOS3 mRNA

NCBI chr 4:11,686,088...11,706,604
Ensembl chr 4:11,686,268...11,706,664

G

NOTUM, palmitoleoyl-protein carboxylesterase

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of NOTUM mRNA]

NCBI chr10:105,933,245...105,940,327
Ensembl chr10:106,431,572...106,438,654

G

neuropeptide Y

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY mRNA

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

neuropeptide Y receptor Y1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NPY1R mRNA

NCBI chr16:27,804,416...27,814,070
Ensembl chr16:27,804,416...27,813,387

G

neuropeptide Y receptor Y2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NPY2R mRNA

NCBI chr 2:170,200,027...170,210,286
Ensembl chr 2:170,200,027...170,210,448

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1H4 mRNA

NCBI chr 7:25,733,471...25,829,440
Ensembl chr 7:25,733,471...25,829,389

G

nuclear receptor subfamily 1, group I, member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR1I2 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:75,965,632...76,002,380

G

nuclear receptor subfamily 5, group A, member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NR5A2 mRNA

NCBI chr13:48,313,634...48,433,494
Ensembl chr13:50,867,920...50,984,938

G

neuropilin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NRP1 mRNA

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702

G

netrin G1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of NTNG1 mRNA

NCBI chr 2:197,462,785...197,827,681
Ensembl chr 2:200,151,979...200,515,031

G

neurotensin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of NTS mRNA

NCBI chr 7:37,564,944...37,574,350
Ensembl chr 7:39,451,073...39,460,961

G

olfactory receptor 1088

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10B1 mRNA

NCBI chr 7:11,111,768...11,115,501
Ensembl chr 7:11,762,338...11,765,415

G

olfactory receptor 1096

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2Z9 mRNA

NCBI chr 7:14,774,197...14,775,147
Ensembl chr 7:15,509,409...15,510,359

G

olfactory receptor 1877

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AD1 mRNA

NCBI chr 7:129,370,144...129,381,836
Ensembl chr 7:131,196,515...131,200,174
Ensembl chr 7:131,196,515...131,200,174

G

olfactory receptor 59

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51E2 mRNA

NCBI chr 1:157,193,051...157,227,707
Ensembl chr 1:166,604,141...166,623,265

G

opsin 1, medium wave sensitive

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPN1MW mRNA

NCBI chr X:151,905,056...151,925,419
Ensembl chr X:157,056,355...157,076,716

G

opioid receptor, delta 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OPRD1 mRNA

NCBI chr 5:144,306,188...144,340,960
Ensembl chr 5:149,590,244...149,624,999

G

opioid receptor, kappa 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OPRK1 mRNA

NCBI chr 5:13,860,016...13,877,823
Ensembl chr 5:18,657,871...18,675,671

G

olfactory receptor family 10 subfamily AL member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR10AL6 mRNA

NCBI chr20:738,257...739,607
Ensembl chr20:743,522...816,076

G

olfactory receptor family 10 subfamily H member 28

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10H28 mRNA

NCBI chr 7:12,591,719...12,592,669

G

olfactory receptor family 10 subfamily J member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR10J3 mRNA

NCBI chr13:85,667,254...85,668,195
Ensembl chr13:88,199,580...88,200,521

G

olfactory receptor family 11 subfamily A member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR11A4 mRNA

NCBI chr20:1,354,527...1,355,468
Ensembl chr20:1,359,776...1,360,717

G

olfactory receptor family 13 subfamily C member 25

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR13C25 mRNA

NCBI chr 5:67,518,691...67,519,650
Ensembl chr 5:72,314,084...72,315,043

G

olfactory receptor family 1 subfamily B member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1B1 mRNA

NCBI chr 3:20,639,976...20,640,929
Ensembl chr 3:41,030,851...41,031,804

G

olfactory receptor family 1 subfamily F member 34

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1F19 mRNA

NCBI chr10:12,333,860...12,334,801

G

olfactory receptor family 1 subfamily M member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1M1 mRNA

NCBI chr 8:16,447,986...16,448,927
Ensembl chr 8:24,724,284...24,725,225

G

olfactory receptor family 1 subfamily Q member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR1Q1 mRNA

NCBI chr 3:20,506,995...20,507,921
Ensembl chr 3:40,897,874...40,898,800

G

olfactory receptor family 1 subfamily R member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR1R1 mRNA

NCBI chr10:58,890,357...58,891,301
Ensembl chr10:59,388,805...59,389,749

G

olfactory receptor family 2 subfamily AG member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2AG2 mRNA

NCBI chr 1:160,695,621...160,696,571
Ensembl chr 1:170,107,441...170,108,391

G

olfactory receptor family 2 subfamily F member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2F2 mRNA

NCBI chr 4:71,740,193...71,741,149
Ensembl chr 4:72,740,216...72,741,172

G

olfactory receptor family 2 subfamily L member 13

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2L13 mRNA

NCBI chr11:81,400,197...81,401,135
Ensembl chr11:94,904,565...94,905,503

G

olfactory receptor family 2 subfamily T member 26

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR2T26 mRNA

NCBI chr10:33,446,540...33,447,493
Ensembl chr10:33,947,662...33,948,615

G

olfactory receptor family 2 subfamily V member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR2V2 mRNA

NCBI chr10:33,379,863...33,380,810
Ensembl chr10:33,880,981...33,881,928

G

olfactory receptor family 3 subfamily A member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR3A4 mRNA

NCBI chr10:58,967,244...58,968,179
Ensembl chr10:59,465,689...59,466,624

G

olfactory receptor family 4 subfamily C member 105

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4C10B mRNA

NCBI chr 3:74,582,417...74,583,346
Ensembl chr 3:95,038,615...95,039,544

G

olfactory receptor family 4 subfamily C member 123

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C123 mRNA

NCBI chr 3:75,272,475...75,273,392
Ensembl chr 3:95,728,654...95,729,571

G

olfactory receptor family 4 subfamily C member 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4C15 mRNA

NCBI chr 3:74,692,006...74,694,901
Ensembl chr 3:95,148,200...95,149,135

G

olfactory receptor family 4 subfamily E member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4E2 mRNA

NCBI chr15:27,661,127...27,662,053
Ensembl chr15:27,661,127...27,662,053

G

olfactory receptor family 4 subfamily F member 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR4F15 mRNA

NCBI chr 3:98,556,667...98,566,115
Ensembl chr 3:119,019,683...119,020,645

G

olfactory receptor family 4 subfamily N member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4N5 mRNA

NCBI chr15:23,167,750...23,168,676
Ensembl chr15:25,647,331...25,648,257

G

olfactory receptor family 4 subfamily Q member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR4Q3 mRNA

NCBI chr15:23,531,029...23,535,992
Ensembl chr15:26,004,612...26,009,053

G

olfactory receptor family 51 subfamily A member 39

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR51A39 mRNA

NCBI chr 1:157,152,386...157,153,348
Ensembl chr 1:166,564,308...166,565,270

G

olfactory receptor family 51 subfamily A member 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51A7 mRNA

NCBI chr 1:157,395,779...157,396,717
Ensembl chr 1:166,807,689...166,808,627

G

olfactory receptor family 51 subfamily B member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51B6 mRNA

NCBI chr 1:158,347,649...158,348,596
Ensembl chr 1:167,759,538...167,760,485

G

olfactory receptor family 51 subfamily D member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51D1 mRNA

NCBI chr 1:157,134,584...157,135,641
Ensembl chr 1:166,546,510...166,547,567

G

olfactory receptor family 51 subfamily G member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR51G1 mRNA

NCBI chr 1:157,438,123...157,439,064
Ensembl chr 1:166,850,033...166,850,974

G

olfactory receptor family 51 subfamily G member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR51G2 mRNA

NCBI chr 1:157,421,637...157,422,575
Ensembl chr 1:166,833,547...166,834,485

G

olfactory receptor family 52 subfamily B member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR52B1 mRNA

NCBI chr 1:159,684,419...159,685,363
Ensembl chr 1:169,096,272...169,097,216

G

olfactory receptor family 52 subfamily E member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR52E8 mRNA

NCBI chr 1:159,360,430...159,361,380
Ensembl chr 1:168,772,296...168,773,246

G

olfactory receptor family 5 subfamily B member 12B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5B12B mRNA

NCBI chr 1:210,042,752...210,043,696
Ensembl chr 1:219,467,328...219,468,272

G

olfactory receptor family 5 subfamily C member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5C1 mRNA

NCBI chr 3:20,862,297...20,863,280
Ensembl chr 3:41,253,167...41,254,150

G

olfactory receptor family 5 subfamily E member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5E1 mRNA

NCBI chr 1:162,724,328...162,725,263
Ensembl chr 1:172,159,177...172,160,112

G

olfactory receptor family 5 subfamily H member 17

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5H19 mRNA

NCBI chr11:41,462,116...41,463,045
Ensembl chr11:54,931,329...54,932,258

G

olfactory receptor family 5 subfamily H member 18

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5H26 mRNA

NCBI chr11:41,405,194...41,423,800
Ensembl chr11:54,859,228...54,893,444

G

olfactory receptor family 5 subfamily K member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR5K3 mRNA

NCBI chr11:41,259,026...41,259,952
Ensembl chr11:54,728,228...54,729,154

G

olfactory receptor family 5 subfamily P member 76B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR5P76 mRNA

NCBI chr 1:162,591,358...162,592,302
Ensembl chr 1:172,023,915...172,024,859

G

olfactory receptor family 6 subfamily B member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6B3 mRNA

NCBI chr 9:93,048,475...93,049,413
Ensembl chr 9:100,495,938...100,496,876

G

olfactory receptor family 6 subfamily C member 1H

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C1B mRNA

NCBI chr 7:2,099,351...2,100,301
Ensembl chr 7:2,727,844...2,728,794

G

olfactory receptor family 6 subfamily C member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C2 mRNA

NCBI chr 7:2,188,601...2,189,539
Ensembl chr 7:2,817,089...2,818,027

G

olfactory receptor family 6 subfamily C member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6C3 mRNA

NCBI chr 7:4,540,307...4,541,242
Ensembl chr 7:5,194,658...5,195,593

G

olfactory receptor family 6 subfamily C member 68

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR6C68 mRNA

NCBI chr 7:5,197,831...5,198,781
Ensembl chr 7:5,848,671...5,849,621

G

olfactory receptor family 6 subfamily C member 74

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C74 mRNA

NCBI chr 7:6,663,296...6,664,234
Ensembl chr 7:7,314,102...7,315,040

G

olfactory receptor family 6 subfamily C member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6C8 mRNA

NCBI chr 7:1,502,160...1,503,089
Ensembl chr 7:2,086,602...2,087,531

G

olfactory receptor family 6 subfamily K member 14B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR6K4 mRNA

NCBI chr13:86,164,244...86,165,191
Ensembl chr13:88,696,573...88,697,520

G

olfactory receptor family 6 subfamily K member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6K6 mRNA

NCBI chr13:86,148,402...86,149,325
Ensembl chr13:88,680,731...88,681,654

G

olfactory receptor family 6 subfamily N member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR6N2 mRNA

NCBI chr13:86,076,857...86,087,100
Ensembl chr13:88,618,188...88,619,141

G

olfactory receptor, family 7, subfamily E, member 178

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR7E178 mRNA

NCBI chr 8:18,723,515...18,735,910
Ensembl chr 8:26,999,759...27,012,158

G

olfactory receptor family 8 subfamily B member 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of OR8B12 mRNA

NCBI chr 8:37,479,706...37,480,638
Ensembl chr 8:45,668,452...45,669,384

G

olfactory receptor family 8 subfamily G member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR8G2 mRNA

NCBI chr 8:40,266,465...40,268,873

G

olfactory receptor family 9 subfamily A member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of OR9A4 mRNA

NCBI chr 4:69,401,606...69,402,550
Ensembl chr 4:70,368,300...70,369,244

G

olfactory receptor family 9 subfamily G member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OR9G4 mRNA

NCBI chr 3:70,727,963...70,728,901
Ensembl chr 3:91,134,643...91,135,581

G

oncostatin M

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSM mRNA

NCBI chr14:83,327,202...83,332,073
Ensembl chr14:83,327,554...83,331,827

G

oncostatin M receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of OSMR mRNA

NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:57,634,517...57,688,561

G

purinergic receptor P2X 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX5 mRNA

NCBI chr10:57,777,737...57,789,426
Ensembl chr10:58,276,257...58,287,935

G

purinergic receptor P2X 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RX7 mRNA

NCBI chr12:39,550,531...39,594,984
Ensembl chr12:39,540,567...39,595,193

G

pyrimidinergic receptor P2Y4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of P2RY4 mRNA

NCBI chr X:69,722,604...69,757,726
Ensembl chr X:69,721,753...69,753,510

G

pyrimidinergic receptor P2Y6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P2RY6 mRNA

NCBI chr 1:164,707,188...164,742,689
Ensembl chr 1:164,706,116...164,743,588

G

prolyl 3-hydroxylase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P3H3 mRNA

NCBI chr 4:157,646,242...157,662,035
Ensembl chr 4:159,332,434...159,348,004

G

prolyl 4-hydroxylase subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:106,335,300...106,346,911

G

phosphoprotein membrane anchor with glycosphingolipid microdomains 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAG1 mRNA

NCBI chr 2:91,935,378...92,076,937
Ensembl chr 2:93,964,594...93,977,227

G

p21 (RAC1) activated kinase 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAK4 mRNA

NCBI chr 1:83,849,904...83,889,188
Ensembl chr 1:92,977,437...93,016,721

G

polyamine oxidase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAOX mRNA

NCBI chr 1:194,919,655...194,928,498
Ensembl chr 1:204,348,987...204,358,481

G

pappalysin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PAPPA mRNA

NCBI chr 5:78,497,660...78,735,873
Ensembl chr 5:83,513,358...83,751,361

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAPSS2 mRNA

NCBI chr 1:239,867,597...239,952,614
Ensembl chr 1:239,867,574...239,952,616

G

poly (ADP-ribose) polymerase 1

multiple interactions

ISO

[Camptothecin co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein; [Plant Extracts co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased cleavage of PARP1 protein

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

paired box 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX4 mRNA

NCBI chr 4:58,023,873...58,032,265
Ensembl chr 4:58,023,914...58,028,858

G

paired box 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PAX6 mRNA

NCBI chr 3:112,590,034...112,611,771
Ensembl chr 3:112,590,391...112,611,763

G

propionyl-CoA carboxylase subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCCB mRNA

NCBI chr 8:101,591,218...101,641,213
Ensembl chr 8:110,469,934...110,520,187

G

proliferating cell nuclear antigen

multiple interactions

EXP
ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PCNA protein]

PMID:17438113 PMID:19028472

NCBI chr 3:139,951,948...139,955,820
Ensembl chr 3:139,951,941...139,955,901

G

procollagen C-endopeptidase enhancer

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PCOLCE mRNA

NCBI chr12:19,084,191...19,090,508
Ensembl chr12:24,720,936...24,727,287

G

phosphodiesterase 10A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE10A mRNA

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:54,317,732...54,764,051

G

phosphodiesterase 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE1A mRNA

NCBI chr 3:85,152,053...85,432,289
Ensembl chr 3:85,154,184...85,519,212

G

phosphodiesterase 1C

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE1C mRNA

NCBI chr 4:85,300,858...85,777,948
Ensembl chr 4:86,626,282...87,193,259

G

phosphodiesterase 2A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE2A mRNA

NCBI chr 1:165,235,623...165,327,466
Ensembl chr 1:165,235,623...165,327,466

G

phosphodiesterase 3A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE3A mRNA

NCBI chr 4:175,904,276...176,170,531
Ensembl chr 4:175,904,077...176,169,270

G

phosphodiesterase 4A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4A mRNA

NCBI chr 8:27,966,978...28,029,721
Ensembl chr 8:27,966,996...28,046,924

G

phosphodiesterase 4B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE4B mRNA

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:122,135,174...122,598,267

G

phosphodiesterase 7A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PDE7A mRNA

NCBI chr 2:101,714,767...101,806,853
Ensembl chr 2:103,634,594...103,722,890

G

phosphodiesterase 7B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDE7B mRNA

NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:17,002,286...17,312,456

G

platelet derived growth factor subunit B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFB mRNA

NCBI chr 7:113,419,882...113,438,343
Ensembl chr 7:113,420,710...113,438,343

G

platelet derived growth factor receptor alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRA mRNA

NCBI chr14:33,360,027...33,408,604
Ensembl chr14:33,360,028...33,408,516

G

platelet derived growth factor receptor beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDGFRB mRNA

NCBI chr18:56,770,348...56,809,228
Ensembl chr18:56,770,348...56,809,233

G

prodynorphin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PDYN mRNA

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:137,354,161...137,366,503

G

platelet factor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PF4 mRNA

NCBI chr14:17,582,477...17,583,392
Ensembl chr14:17,582,477...17,583,392

G

phosphoglucomutase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:119,710,737...119,770,159

G

phosphoglucomutase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PGM3 mRNA

NCBI chr 8:96,398,331...96,416,045
Ensembl chr 8:96,398,269...96,416,021

G

phosphorylase kinase regulatory subunit alpha 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKA1 mRNA

NCBI chr X:71,639,701...71,778,465
Ensembl chr X:71,641,246...71,778,320

G

phosphorylase kinase regulatory subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PHKB mRNA

NCBI chr19:21,013,719...21,210,671
Ensembl chr19:37,186,042...37,383,877

G

phosphoinositide-3-kinase adaptor protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PIK3AP1 mRNA

NCBI chr 1:240,090,854...240,245,007
Ensembl chr 1:250,040,250...250,154,226

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PIK3CA mRNA

NCBI chr 2:117,103,643...117,177,411
Ensembl chr 2:117,143,468...117,177,411

G

pyruvate kinase L/R

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PKLR mRNA

NCBI chr 2:176,840,779...176,849,637
Ensembl chr 2:176,840,764...176,849,644

G

phospholipase A2, group X

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G10 mRNA

NCBI chr10:2,104,927...2,117,998
Ensembl chr10:2,104,927...2,116,172

G

phospholipase A2, group XIIA

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G12A mRNA

NCBI chr 2:218,436,497...218,452,742
Ensembl chr 2:221,110,685...221,126,964

G

phospholipase A2, group XIIB

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G12B mRNA

NCBI chr20:27,369,196...27,389,517
Ensembl chr20:27,913,259...27,932,148

G

phospholipase A2 group IIA

multiple interactions
increases expression
increases activity

EXP

Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased activity of PLA2G2A protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PLA2G2A mRNA]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PLA2G2A protein]
Azoxymethane results in increased expression of PLA2G2A mRNA; Azoxymethane results in increased expression of PLA2G2A protein

NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297

G

phospholipase A2, group IIC

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLA2G2C mRNA

NCBI chr 5:156,241,142...156,262,368
Ensembl chr 5:156,242,451...156,264,676

G

phospholipase A2, group IIE

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2E mRNA

NCBI chr 5:156,404,639...156,410,421
Ensembl chr 5:156,404,639...156,410,408

G

phospholipase A2, group IIF

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G2F mRNA

NCBI chr 5:156,270,077...156,276,464
Ensembl chr 5:156,270,077...156,295,516

G

phospholipase A2, group IVF

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLA2G4F mRNA

NCBI chr 3:107,249,053...107,266,201
Ensembl chr 3:127,703,841...127,718,348

G

plasminogen activator, tissue type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAT mRNA

NCBI chr16:75,943,061...76,022,037
Ensembl chr16:75,943,064...75,967,696

G

plasminogen activator, urokinase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAU mRNA

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

plasminogen activator, urokinase receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLAUR mRNA

NCBI chr 1:89,181,363...89,196,308
Ensembl chr 1:89,178,453...89,198,130

G

phospholipase C, beta 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLCB2 mRNA

NCBI chr 3:105,683,676...105,704,384
Ensembl chr 3:126,138,736...126,158,221

G

phospholipase C, beta 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCB4 mRNA

NCBI chr 3:122,952,965...123,322,522
Ensembl chr 3:143,405,950...143,775,113

G

phospholipase C, epsilon 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PLCE1 mRNA

NCBI chr 1:245,655,855...245,964,966
Ensembl chr 1:245,657,080...245,963,828

G

pleckstrin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLEK mRNA

NCBI chr14:95,598,650...95,631,326
Ensembl chr14:95,598,654...95,655,721

G

plasminogen

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLG mRNA

NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:50,872,926...50,917,320

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PLOD2 mRNA

NCBI chr 8:101,964,318...102,047,022
Ensembl chr 8:101,964,318...102,047,022

G

phosphomannomutase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PMM2 mRNA

NCBI chr10:6,961,521...6,982,913
Ensembl chr10:7,468,372...7,489,554

G

pancreatic lipase-related protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PNLIPRP1 mRNA

NCBI chr 1:257,867,885...257,883,514
Ensembl chr 1:267,854,027...267,869,654

G

peroxisome proliferator activated receptor alpha

affects response to substance
multiple interactions

ISO

PPARA protein affects the susceptibility to Azoxymethane
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARA mRNA

PMID:29950665 PMID:33458792

NCBI chr 7:118,712,261...118,780,723
Ensembl chr 7:118,712,412...118,780,714

G

peroxisome proliferator-activated receptor delta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARD mRNA

NCBI chr20:6,300,527...6,365,707
Ensembl chr20:6,352,183...6,365,707

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PPARG mRNA

NCBI chr 4:150,095,743...150,221,104
Ensembl chr 4:150,095,787...150,221,104

G

protein phosphatase 3 catalytic subunit gamma

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPP3CC mRNA

NCBI chr15:45,289,917...45,362,012
Ensembl chr15:51,700,255...51,771,538

G

pancreatic polypeptide

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PPY mRNA

NCBI chr10:87,054,747...87,056,044
Ensembl chr10:87,554,950...87,556,719

G

protein kinase cAMP-activated catalytic subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKACB mRNA

NCBI chr 2:238,297,140...238,389,317
Ensembl chr 2:238,300,127...238,386,315

G

protein kinase AMP-activated non-catalytic subunit gamma 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKAG2 mRNA

NCBI chr 4:10,010,890...10,252,155
Ensembl chr 4:10,744,588...10,985,939

G

protein kinase C, alpha

multiple interactions
increases expression

ISO
EXP

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKCA mRNA
Azoxymethane results in increased expression of PRKCA mRNA

PMID:11983831 PMID:29950665

NCBI chr10:93,388,991...93,787,617
Ensembl chr10:93,388,991...93,787,572

G

protein kinase C, beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCB mRNA; Azoxymethane results in increased phosphorylation of and results in increased activity of PRKCB protein; pterostilbene inhibits the reaction [Azoxymethane results in increased phosphorylation of and results in increased activity of PRKCB protein]

PMID:21355597 PMID:29950665

NCBI chr 1:186,263,397...186,594,743
Ensembl chr 1:186,263,447...186,594,740

G

protein kinase C, delta

increases expression

EXP

Azoxymethane results in increased expression of PRKCD mRNA

NCBI chr16:5,775,681...5,806,122
Ensembl chr16:5,775,681...5,805,839

G

protein kinase C, theta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRKCQ mRNA

NCBI chr17:72,156,215...72,288,508
Ensembl chr17:72,156,215...72,288,508

G

protein kinase cGMP-dependent 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRKG2 mRNA

NCBI chr14:10,559,882...10,668,479
Ensembl chr14:10,864,186...10,972,614

G

prolactin family 3, subfamily D member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRL3D1 mRNA

G

prolactin receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PRLR mRNA

NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:60,861,658...61,051,882

G

protein C, inactivator of coagulation factors Va and VIIIa

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PROC mRNA

NCBI chr18:23,764,367...23,774,816
Ensembl chr18:24,038,597...24,048,964

G

protein S

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PROS1 mRNA

NCBI chr11:230,597...311,288
Ensembl chr11:13,676,769...13,757,852

G

serine protease 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRSS3 mRNA; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY4 mRNA

NCBI chr 4:70,203,088...70,206,562
Ensembl chr 4:71,169,749...71,173,223

G

peroxiredoxin like 2B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PRXL2B mRNA

NCBI chr 5:165,462,610...165,465,213
Ensembl chr 5:170,744,953...170,747,556

G

presenilin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PSEN1 mRNA

NCBI chr 6:109,054,160...109,106,191
Ensembl chr 6:109,060,352...109,106,189

G

proline-serine-threonine phosphatase-interacting protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PSTPIP1 mRNA

NCBI chr 8:65,395,328...65,434,616
Ensembl chr 8:65,395,358...65,434,627

G

platelet-activating factor receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTAFR mRNA

NCBI chr 5:150,049,322...150,079,060
Ensembl chr 5:150,049,460...150,079,408

G

prostaglandin D2 receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDR2 mRNA

NCBI chr 1:217,010,183...217,015,044
Ensembl chr 1:216,995,629...217,022,393

G

prostaglandin D2 synthase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGDS mRNA

NCBI chr 3:8,281,899...8,284,833
Ensembl chr 3:28,680,044...28,682,978

G

prostaglandin E receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER2 mRNA

NCBI chr15:18,215,013...18,228,714
Ensembl chr15:20,696,013...20,708,950

G

prostaglandin E receptor 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGER3 mRNA

NCBI chr 2:249,264,985...249,409,966
Ensembl chr 2:249,264,985...249,409,846

G

prostaglandin E receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGER4 mRNA

NCBI chr 2:56,061,699...56,074,594
Ensembl chr 2:56,062,890...56,074,135

G

prostaglandin E synthase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGES mRNA

NCBI chr 3:14,177,892...14,189,236
Ensembl chr 3:34,575,639...34,586,995

G

prostaglandin F receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGFR mRNA

NCBI chr 2:240,731,185...240,766,674
Ensembl chr 2:243,393,350...243,425,623

G

prostaglandin I2 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIR mRNA

NCBI chr 1:77,579,596...77,581,979
Ensembl chr 1:86,707,503...86,711,874

G

prostaglandin I2 synthase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGIS mRNA

NCBI chr 3:155,928,564...155,964,228
Ensembl chr 3:176,335,437...176,407,650

G

prostaglandin reductase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGR1 mRNA

NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:78,579,057...78,597,811

G

prostaglandin-endoperoxide synthase 1

decreases expression

EXP

Azoxymethane results in decreased expression of PTGS1 mRNA

NCBI chr 3:39,981,419...40,002,993
Ensembl chr 3:39,981,415...40,002,990

G

prostaglandin-endoperoxide synthase 2

increases expression
multiple interactions

ISO
EXP

Azoxymethane results in increased expression of PTGS2 mRNA; Azoxymethane results in increased expression of PTGS2 protein
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTGS2 mRNA; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 mRNA]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTGS2 protein]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of PTGS2 mRNA]; pterostilbene inhibits the reaction [Azoxymethane results in increased expression of PTGS2 protein]; Resveratrol inhibits the reaction [Azoxymethane results in increased expression of PTGS2 mRNA]; Resveratrol inhibits the reaction [Azoxymethane results in increased expression of PTGS2 protein]
[Curcumin co-treated with Azoxymethane] results in increased expression of PTGS2 mRNA; Ro 24-5531 inhibits the reaction [Azoxymethane results in increased expression of PTGS2 protein]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PTGS2 mRNA]; Ursodeoxycholic Acid inhibits the reaction [Azoxymethane results in increased expression of PTGS2 protein]; xanthohumol inhibits the reaction [Azoxymethane results in increased expression of PTGS2 mRNA]

PMID:12458338 PMID:12496057 PMID:12839936 PMID:17190766 PMID:17438113 More...

NCBI chr13:64,714,063...64,722,320
Ensembl chr13:64,713,619...64,722,320

G

parathyroid hormone 1 receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTH1R mRNA

NCBI chr 8:119,572,295...119,597,405
Ensembl chr 8:119,575,868...119,598,108

G

parathyroid hormone-like hormone

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PTHLH mRNA

NCBI chr 4:181,919,400...181,930,454
Ensembl chr 4:181,919,400...181,930,454

G

protein tyrosine phosphatase 4A3

increases expression

ISO

Azoxymethane results in increased expression of PTP4A3 mRNA; Azoxymethane results in increased expression of PTP4A3 protein

NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:107,541,047...107,549,949

G

protein tyrosine phosphatase, receptor type, U

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of PTPRU mRNA

NCBI chr 5:143,950,542...144,024,791
Ensembl chr 5:149,234,624...149,308,833

G

peptide YY

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of PYY mRNA

NCBI chr10:87,061,155...87,062,278
Ensembl chr10:87,561,353...87,562,206

G

RAB27B, member RAS oncogene family

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RAB27B mRNA

NCBI chr18:63,597,554...63,794,124
Ensembl chr18:65,876,342...66,067,700

G

Rac family small GTPase 3

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of RAC3 mRNA]

NCBI chr10:106,501,133...106,503,569
Ensembl chr10:106,501,135...106,503,569

G

receptor activity modifying protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP1 mRNA

NCBI chr 9:91,765,481...91,816,152

G

receptor activity modifying protein 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP2 mRNA

NCBI chr10:86,187,366...86,190,692
Ensembl chr10:86,688,703...86,691,231

G

receptor activity modifying protein 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAMP3 mRNA

NCBI chr14:85,741,314...85,758,813
Ensembl chr14:85,755,211...85,758,818

G

Rap guanine nucleotide exchange factor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RAPGEF4 mRNA

NCBI chr 3:77,217,024...77,509,933
Ensembl chr 3:77,217,039...77,509,978

G

retinoic acid receptor, gamma

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RARG mRNA

NCBI chr 7:135,246,427...135,268,889
Ensembl chr 7:135,246,427...135,268,889

G

RAS guanyl releasing protein 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RASGRP3 mRNA

NCBI chr 6:19,895,361...19,993,945
Ensembl chr 6:25,647,386...25,710,591

G

RELA proto-oncogene, NF-kB subunit

increases phosphorylation
multiple interactions

ISO

Azoxymethane results in increased phosphorylation of RELA protein
[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RELA protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] affects the localization of and results in increased phosphorylation of RELA protein]; pterostilbene inhibits the reaction [Azoxymethane results in increased phosphorylation of RELA protein]; Resveratrol inhibits the reaction [Azoxymethane results in increased phosphorylation of RELA protein]

PMID:21355597 PMID:25449198 PMID:34273909

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

renin binding protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RENBP mRNA

NCBI chr X:151,661,463...151,670,538
Ensembl chr X:156,812,411...156,821,838

G

retinol saturase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RETSAT mRNA

NCBI chr 4:106,211,459...106,220,222
Ensembl chr 4:106,211,436...106,229,552

G

retinal G protein coupled receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGR mRNA

NCBI chr16:12,801,594...12,816,402
Ensembl chr16:12,821,858...12,836,486

G

regulator of G-protein signaling 19

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS19 mRNA

NCBI chr 3:168,804,532...168,813,035
Ensembl chr 3:189,182,383...189,190,736

G

regulator of G-protein signaling 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RGS7 mRNA

NCBI chr13:86,979,269...87,408,834
Ensembl chr13:89,511,150...89,940,987

G

Rh family B glycoprotein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RHBG mRNA

NCBI chr 2:176,002,886...176,015,201
Ensembl chr 2:176,002,887...176,015,609

G

ras homolog family member J

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RHOJ mRNA

NCBI chr 6:99,771,104...99,853,366
Ensembl chr 6:99,771,252...99,853,999

G

ribosomal protein S6

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:106,417,680...106,420,566

G

RT1 class Ib, locus M3, gene 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of H2-M3 mRNA

NCBI chr20:1,329,227...1,333,394
Ensembl chr20:1,329,225...1,333,366

G

relaxin family peptide receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP1 mRNA

NCBI chr 2:164,772,270...164,893,484
Ensembl chr 2:167,070,417...167,191,556

G

relaxin family peptide/INSL5 receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RXFP4 mRNA

NCBI chr 2:176,421,332...176,422,486

G

retinoid X receptor alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of RXRA mRNA

NCBI chr 3:31,387,892...31,474,415
Ensembl chr 3:31,388,223...31,474,417

G

ryanodine receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of RYR1 mRNA

NCBI chr 1:84,292,578...84,423,824
Ensembl chr 1:93,420,078...93,551,305

G

S100 calcium binding protein G

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of S100G mRNA

NCBI chr X:35,337,636...35,340,205
Ensembl chr X:35,337,675...35,340,205

G

sphingosine-1-phosphate receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of S1PR2 mRNA

NCBI chr 8:27,779,452...27,790,344
Ensembl chr 8:27,774,566...27,790,577

G

secretoglobin family 1A member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SCGB1A1 mRNA

NCBI chr 1:215,406,138...215,409,686
Ensembl chr 1:215,406,138...215,409,686

G

scinderin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCIN mRNA

NCBI chr 6:62,836,641...62,915,287
Ensembl chr 6:62,836,641...62,915,287

G

sodium channel epithelial 1 subunit alpha

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1A mRNA

NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405

G

sodium channel epithelial 1 subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCNN1B mRNA

NCBI chr 1:185,861,326...185,915,717
Ensembl chr 1:185,854,733...185,916,049

G

secretin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SCT mRNA

NCBI chr 1:205,812,435...205,813,246
Ensembl chr 1:205,812,435...205,813,246

G

syndecan 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SDC3 mRNA

NCBI chr 5:148,249,792...148,282,524
Ensembl chr 5:148,271,842...148,280,614

G

selectin P

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SELP mRNA

NCBI chr13:79,009,379...79,044,994
Ensembl chr13:79,009,475...79,044,987

G

serpin family E member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:25,237,952...25,248,357

G

serpin family G member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SERPING1 mRNA

NCBI chr 3:90,249,410...90,259,299
Ensembl chr 3:90,249,423...90,258,717

G

serum/glucocorticoid regulated kinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SGK2 mRNA

NCBI chr 3:151,644,102...151,669,480
Ensembl chr 3:172,063,776...172,089,011

G

SH3 domain containing GRB2 like 2, endophilin A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SH3GL2 mRNA

NCBI chr 5:99,653,189...99,827,500
Ensembl chr 5:104,698,929...105,159,896

G

SH3 domain-containing kinase-binding protein 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SH3KBP1 mRNA

NCBI chr X:34,877,862...35,223,013
Ensembl chr X:38,686,530...39,031,393

G

signal-induced proliferation-associated 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SIPA1 mRNA

NCBI chr 1:202,938,532...202,950,672
Ensembl chr 1:212,367,867...212,377,497

G

solute carrier family 10 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC10A2 mRNA

NCBI chr16:84,386,528...84,409,475
Ensembl chr16:91,076,423...91,111,025

G

solute carrier family 10 member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC10A6 mRNA

NCBI chr14:6,080,716...6,102,902
Ensembl chr14:6,385,537...6,408,894

G

solute carrier family 11 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC11A1 mRNA

NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:83,406,427...83,417,238

G

solute carrier family 12 member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC12A4 mRNA

NCBI chr19:33,838,418...33,860,369
Ensembl chr19:50,748,279...50,770,259

G

solute carrier family 12 member 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC12A7 mRNA

NCBI chr 1:29,472,692...29,554,246
Ensembl chr 1:31,301,243...31,382,957

G

solute carrier family 13 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A1 mRNA

NCBI chr 4:52,569,179...52,647,126
Ensembl chr 4:53,534,768...53,612,704

G

solute carrier family 13 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A2 mRNA

NCBI chr10:63,291,813...63,319,127
Ensembl chr10:63,789,876...63,817,184

G

solute carrier family 13 member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC13A5 mRNA

NCBI chr10:57,364,806...57,389,500
Ensembl chr10:57,364,806...57,389,516

G

solute carrier family 15 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC15A1 mRNA

NCBI chr15:98,537,641...98,582,544
Ensembl chr15:104,944,463...104,989,369

G

solute carrier family 15 member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC15A4 mRNA

NCBI chr12:29,048,634...29,082,480
Ensembl chr12:34,698,955...34,719,819

G

solute carrier family 16 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A3 mRNA

NCBI chr10:106,712,328...106,756,168
Ensembl chr10:106,714,466...106,720,903

G

solute carrier family 16 member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC16A8 mRNA

NCBI chr 7:112,698,701...112,702,496
Ensembl chr 7:112,698,701...112,702,496

G

solute carrier family 17 member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A5 mRNA

NCBI chr 8:88,274,497...88,309,734
Ensembl chr 8:88,274,721...88,309,664

G

solute carrier family 17 member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC17A6 mRNA

NCBI chr 1:110,348,447...110,388,499
Ensembl chr 1:110,348,447...110,388,498

G

solute carrier family 17 member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC17A8 mRNA

NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:25,881,557...25,935,410

G

solute carrier family 18 member A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC18A1 mRNA

NCBI chr16:20,653,268...20,687,051
Ensembl chr16:25,420,243...25,453,786

G

solute carrier family 19 member 1

increases response to substance

ISO

SLC19A1 gene mutant form results in increased susceptibility to Azoxymethane

NCBI chr20:11,583,928...11,601,959
Ensembl chr20:11,583,929...11,601,488

G

solute carrier family 1 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A2 mRNA

NCBI chr 3:109,460,109...109,590,445
Ensembl chr 3:109,459,630...109,605,249

G

solute carrier family 1 member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A6 mRNA

NCBI chr 7:10,841,836...10,870,424
Ensembl chr 7:11,492,422...11,553,997

G

solute carrier family 1 member 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC1A7 mRNA

NCBI chr 5:122,731,003...122,775,139
Ensembl chr 5:127,959,769...128,003,899

G

solute carrier family 22 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A1 mRNA

NCBI chr 1:50,624,339...50,651,437
Ensembl chr 1:50,624,377...50,651,436

G

solute carrier family 22, member 18

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A18 mRNA

NCBI chr 1:198,670,626...198,694,977
Ensembl chr 1:208,101,136...208,124,380

G

solute carrier family 22 (organic cation transporter), member 21

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A21 mRNA

NCBI chr10:38,104,114...38,133,106
Ensembl chr10:38,604,886...38,631,209

G

solute carrier family 22 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A3 mRNA

NCBI chr 1:50,783,218...50,872,358
Ensembl chr 1:50,783,218...50,872,353

G

solute carrier family 22 member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC22A4 mRNA

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,634,098...38,679,920

G

solute carrier family 22 member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A5 mRNA

NCBI chr10:38,509,072...38,536,240
Ensembl chr10:38,509,072...38,536,077

G

solute carrier family 22 member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC22A8 mRNA

NCBI chr 1:214,925,506...214,945,516
Ensembl chr 1:214,925,508...214,946,588

G

solute carrier family 25 member 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC25A10 mRNA

NCBI chr10:105,765,598...105,775,159
Ensembl chr10:106,264,344...106,273,498

G

solute carrier family 25 member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC25A4 mRNA

NCBI chr16:52,805,521...52,809,316
Ensembl chr16:52,805,523...52,811,700

G

solute carrier family 26 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A1 mRNA

NCBI chr14:1,180,465...1,190,257
Ensembl chr14:1,184,649...1,190,255

G

solute carrier family 26 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A2 mRNA

NCBI chr18:54,648,276...54,666,627
Ensembl chr18:56,923,337...56,937,012

G

solute carrier family 26 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A3 mRNA

NCBI chr 6:48,023,892...48,064,829
Ensembl chr 6:53,751,415...53,792,294

G

solute carrier family 26 member 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC26A7 mRNA

NCBI chr 5:32,681,653...32,819,110
Ensembl chr 5:32,684,288...32,818,905

G

solute carrier family 26 member 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC26A9 mRNA

NCBI chr13:43,177,806...43,205,450
Ensembl chr13:45,730,082...45,757,660

G

solute carrier family 27 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A1 mRNA

NCBI chr16:18,278,984...18,300,173
Ensembl chr16:18,313,015...18,330,045

G

solute carrier family 27 member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC27A4 mRNA

NCBI chr 3:33,472,903...33,485,824
Ensembl chr 3:33,472,903...33,485,824

G

solute carrier family 28 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC28A3 mRNA

NCBI chr17:6,062,563...6,112,965
Ensembl chr17:6,068,060...6,120,417

G

solute carrier family 29 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC29A2 mRNA

NCBI chr 1:211,756,588...211,764,561
Ensembl chr 1:211,757,000...211,764,560

G

solute carrier family 2 member 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A12 mRNA

NCBI chr 1:22,803,068...22,862,204
Ensembl chr 1:24,589,707...24,694,290

G

solute carrier family 2 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC2A3 mRNA

NCBI chr 4:157,632,887...157,698,034
Ensembl chr 4:157,632,887...157,646,186

G

solute carrier family 30 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC30A1 mRNA

NCBI chr13:106,022,019...106,025,892
Ensembl chr13:106,022,019...106,025,892

G

solute carrier family 30 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC30A2 mRNA

NCBI chr 5:146,559,733...146,571,957
Ensembl chr 5:151,843,389...151,855,670

G

solute carrier family 34 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC34A2 mRNA

NCBI chr14:57,910,931...57,930,236
Ensembl chr14:62,123,316...62,143,360

G

solute carrier family 35 member A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A1 mRNA

NCBI chr 5:49,225,599...49,248,382
Ensembl chr 5:54,021,896...54,044,677

G

solute carrier family 35 member A3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35A3 mRNA

NCBI chr 2:204,620,103...204,659,319
Ensembl chr 2:207,307,947...207,344,155

G

solute carrier family 35 member D1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D1 mRNA

NCBI chr 5:117,928,628...117,981,289
Ensembl chr 5:123,155,407...123,210,073

G

solute carrier family 35 member D2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC35D2 mRNA

NCBI chr17:987,899...1,019,747
Ensembl chr17:993,646...1,025,475

G

solute carrier family 36 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC36A1 mRNA

NCBI chr10:39,319,062...39,357,374
Ensembl chr10:39,825,023...39,858,066

G

solute carrier family 39 member 10

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A10 mRNA

NCBI chr 9:54,836,841...54,960,325
Ensembl chr 9:62,370,598...62,454,747

G

solute carrier family 39 member 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A14 mRNA

NCBI chr15:51,786,517...51,833,260
Ensembl chr15:51,786,623...51,833,229

G

solute carrier family 39 member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A4 mRNA

NCBI chr 7:108,333,368...108,337,553
Ensembl chr 7:110,214,017...110,218,202

G

solute carrier family 39 member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A5 mRNA

NCBI chr 7:1,409,360...1,415,407
Ensembl chr 7:1,409,360...1,414,784

G

solute carrier family 39 member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC39A6 mRNA

NCBI chr18:15,864,874...15,885,417
Ensembl chr18:16,135,008...16,160,163

G

solute carrier family 39 member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC39A8 mRNA

NCBI chr 2:226,845,686...226,992,668
Ensembl chr 2:226,929,644...226,992,667

G

solute carrier family 3 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC3A1 mRNA

NCBI chr 6:9,608,169...9,641,881
Ensembl chr 6:15,361,046...15,394,775

G

solute carrier family 40 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC40A1 mRNA

NCBI chr 9:55,525,457...55,633,463
Ensembl chr 9:55,525,532...55,543,460

G

solute carrier family 44, member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A3 mRNA

NCBI chr 2:209,552,138...209,628,182
Ensembl chr 2:212,236,853...212,312,982

G

solute carrier family 44, member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC44A4 mRNA

NCBI chr20:3,903,099...3,919,215
Ensembl chr20:3,907,737...3,923,854

G

solute carrier family 46 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC46A1 mRNA

NCBI chr10:63,859,551...63,865,987
Ensembl chr10:63,859,504...63,866,869

G

solute carrier family 47 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A1 mRNA

NCBI chr10:46,533,580...46,590,128
Ensembl chr10:46,533,583...46,587,096

G

solute carrier family 47 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC47A2 mRNA

NCBI chr10:45,990,806...46,033,937
Ensembl chr10:46,489,831...46,533,425

G

solute carrier family 4 member 1 (Diego blood group)

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A1 mRNA

NCBI chr10:87,807,010...87,823,274
Ensembl chr10:87,807,013...87,823,258

G

solute carrier family 4 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A2 mRNA

NCBI chr 4:11,628,860...11,646,961
Ensembl chr 4:11,628,862...11,645,402

G

solute carrier family 4 member 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC4A7 mRNA

NCBI chr15:13,015,854...13,095,485
Ensembl chr15:13,015,854...13,095,292

G

solute carrier family 51 member A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51A mRNA

NCBI chr11:81,804,141...81,818,539
Ensembl chr11:81,803,972...81,818,539

G

SLC51 subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC51B mRNA

NCBI chr 8:74,827,047...74,835,109
Ensembl chr 8:74,827,047...74,835,109

G

solute carrier family 52 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC52A2 mRNA

NCBI chr 7:108,246,003...108,267,642
Ensembl chr 7:110,143,220...110,158,809

G

solute carrier family 5 member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A1 mRNA

NCBI chr14:81,778,495...81,843,084
Ensembl chr14:81,778,348...81,846,624

G

solute carrier family 5 member 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A11 mRNA

NCBI chr 1:177,735,511...177,795,193
Ensembl chr 1:187,166,811...187,282,848

G

solute carrier family 5 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of SLC5A3 mRNA

NCBI chr11:44,799,787...44,802,233
Ensembl chr11:44,790,297...44,818,157

G

solute carrier family 5 member 8

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A8 mRNA

NCBI chr 7:25,160,280...25,201,185
Ensembl chr 7:25,159,897...25,204,419

G

solute carrier family 5 member 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC5A9 mRNA

NCBI chr 5:126,709,762...126,733,468
Ensembl chr 5:131,938,216...131,961,922

G

solute carrier family 6 member 11

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A11 mRNA

NCBI chr 4:147,297,972...147,413,319
Ensembl chr 4:148,853,554...148,969,019

G

solute carrier family 6 member 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A12 mRNA

NCBI chr 4:156,257,518...156,275,870
Ensembl chr 4:156,254,208...156,275,879

G

solute carrier family 6 member 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A14 mRNA

NCBI chr X:112,314,643...112,375,412
Ensembl chr X:117,108,947...117,169,828

G

solute carrier family 6 member 19

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A19 mRNA

NCBI chr 1:29,586,191...29,604,964
Ensembl chr 1:31,414,744...31,433,517

G

solute carrier family 6 member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC6A2 mRNA

NCBI chr19:30,183,289...30,228,292
Ensembl chr19:30,183,383...30,223,348

G

solute carrier family 6 member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A3 mRNA

NCBI chr 1:31,537,990...31,578,962
Ensembl chr 1:31,537,990...31,578,962

G

solute carrier family 6 member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC6A6 mRNA

NCBI chr 4:125,752,340...125,826,033
Ensembl chr 4:125,752,372...125,826,032

G

solute carrier family 7 member 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A5 mRNA

NCBI chr19:66,843,808...66,872,412
Ensembl chr19:66,843,808...66,872,412

G

solute carrier family 7 member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC7A6 mRNA

NCBI chr19:34,073,472...34,100,268
Ensembl chr19:50,984,132...51,010,134

G

solute carrier family 7 member 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC7A9 mRNA

NCBI chr 1:88,109,517...88,132,653
Ensembl chr 1:97,247,547...97,269,543

G

solute carrier family 8 member A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A1 mRNA

NCBI chr 6:18,975,498...19,299,704
Ensembl chr 6:18,946,798...19,287,964

G

solute carrier family 8 member A3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC8A3 mRNA

NCBI chr 6:106,605,611...106,739,208
Ensembl chr 6:106,605,621...106,721,412

G

solute carrier family 9 member A2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A2 mRNA

NCBI chr 9:42,932,001...43,014,447
Ensembl chr 9:50,426,798...50,510,040

G

solute carrier family 9 member A3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLC9A3 mRNA

NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:30,953,216...30,996,002

G

solute carrier family 9 member A7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLC9A7 mRNA

NCBI chr X:4,767,578...4,948,602
Ensembl chr X:4,767,915...4,948,602

G

solute carrier organic anion transporter family, member 1a4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO1A4 mRNA

NCBI chr 4:176,441,104...176,495,846
Ensembl chr 4:176,441,104...176,495,816

G

solute carrier organic anion transporter family, member 2b1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SLCO2B1 mRNA

NCBI chr 1:163,371,410...163,419,412
Ensembl chr 1:163,371,410...163,419,279

G

solute carrier organic anion transporter family, member 3a1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SLCO3A1 mRNA

NCBI chr 1:137,516,037...137,797,836
Ensembl chr 1:137,505,158...137,797,836

G

smoothened, frizzled class receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMO mRNA

NCBI chr 4:59,311,084...59,341,280
Ensembl chr 4:59,311,041...59,341,281

G

spermine oxidase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SMOX mRNA

NCBI chr 3:118,731,814...118,767,242
Ensembl chr 3:139,184,798...139,220,170
Ensembl chr X:139,184,798...139,220,170

G

snail family transcriptional repressor 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SNAI1 protein

NCBI chr 3:156,248,479...156,252,969

G

SRY-box transcription factor 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SOX9 mRNA

NCBI chr10:98,305,744...98,311,250
Ensembl chr10:98,305,744...98,311,250

G

secreted protein acidic and cysteine rich

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPARC mRNA

NCBI chr10:40,017,065...40,038,816
Ensembl chr10:40,017,075...40,039,268

G

sphingosine kinase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPHK1 mRNA

NCBI chr10:102,257,413...102,263,086
Ensembl chr10:102,258,975...102,263,082

G

sialophorin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SPN mRNA

NCBI chr 1:191,177,449...191,190,115
Ensembl chr 1:191,178,096...191,187,852

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

EXP

[[Azoxymethane co-treated with Sulindac] results in increased expression of CSK protein] which results in increased phosphorylation of and results in decreased activity of SRC protein

NCBI chr 3:166,511,616...166,559,463
Ensembl chr 3:166,511,985...166,559,462

G

steroid 5 alpha-reductase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of SRD5A2 mRNA

NCBI chr 6:27,178,089...27,217,588
Ensembl chr 6:27,178,079...27,217,588

G

SLIT-ROBO Rho GTPase activating protein 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SRGAP3 mRNA

NCBI chr 4:145,839,369...146,070,556
Ensembl chr 4:147,395,880...147,625,713

G

somatostatin receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SSTR1 mRNA

NCBI chr 6:81,567,237...81,571,759
Ensembl chr 6:81,566,850...81,571,992

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of ST3GAL3 mRNA

NCBI chr 5:131,470,348...131,670,794
Ensembl chr 5:136,755,678...136,955,987

G

ST3 beta-galactoside alpha-2,3-sialyltransferase 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of ST3GAL6 mRNA

NCBI chr11:42,061,282...42,121,801
Ensembl chr11:55,530,248...55,598,720

G

StAR-related lipid transfer domain containing 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STARD5 mRNA

NCBI chr 1:137,606,151...137,616,017
Ensembl chr 1:147,015,299...147,026,351

G

signal transducer and activator of transcription 1

multiple interactions

EXP

[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Azoxymethane] results in increased expression of STAT1 mRNA

NCBI chr 9:56,911,522...56,951,926
Ensembl chr 9:56,911,523...57,077,346

G

signal transducer and activator of transcription 3

multiple interactions

EXP
ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STAT3 protein]
[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein; [Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein; CEP 33779 inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of and results in increased phosphorylation of STAT3 protein]; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased phosphorylation of STAT3 protein]

PMID:19028472 PMID:22334590 PMID:25026504

NCBI chr10:86,311,528...86,363,513
Ensembl chr10:86,311,535...86,363,359

G

STEAP family member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP1 mRNA

NCBI chr 4:28,276,972...28,287,484
Ensembl chr 4:29,231,753...29,242,317

G

STEAP2 metalloreductase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STEAP2 mRNA

NCBI chr 4:28,347,769...28,368,177
Ensembl chr 4:29,303,381...29,330,620

G

stromal interaction molecule 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of STIM1 mRNA

NCBI chr 1:166,067,450...166,230,733
Ensembl chr 1:166,067,962...166,233,108

G

syntaxin 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of STX1A mRNA

NCBI chr12:27,278,517...27,306,547
Ensembl chr12:27,278,517...27,306,471

G

succinate-CoA ligase GDP-forming subunit beta

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SUCLG2 mRNA

NCBI chr 4:128,067,031...128,337,146
Ensembl chr 4:129,623,834...129,937,296

G

sulfotransferase family 1B member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1B1 mRNA

NCBI chr14:20,492,763...20,505,491
Ensembl chr14:20,771,868...20,785,549

G

sulfotransferase family 1C member 2A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of SULT1C2 mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:7,066,905...7,244,132

G

trace amine-associated receptor 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAAR5 mRNA

NCBI chr 1:21,469,923...21,470,936
Ensembl chr 1:23,289,163...23,290,176

G

tachykinin, precursor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAC1 mRNA

NCBI chr 4:36,645,344...36,653,548
Ensembl chr 4:36,645,571...36,653,546

G

tachykinin receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TACR1 mRNA

NCBI chr 4:116,478,617...116,647,492
Ensembl chr 4:116,478,617...116,647,492

G

tachykinin receptor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TACR2 mRNA

NCBI chr20:30,208,907...30,223,446
Ensembl chr20:30,751,557...30,766,180

G

T-cell activation RhoGTPase activating protein

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAGAP mRNA

NCBI chr 1:47,170,725...47,179,705
Ensembl chr 1:49,575,750...49,583,838

G

transporter 1, ATP binding cassette subfamily B member

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAP1 mRNA

NCBI chr20:4,658,171...4,668,543
Ensembl chr20:4,658,172...4,668,810

G

taste 1 receptor member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TAS1R2 mRNA

NCBI chr 5:151,909,617...151,925,760
Ensembl chr 5:157,192,799...157,208,937

G

taste 1 receptor member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS1R3 mRNA

NCBI chr 5:166,468,703...166,472,759
Ensembl chr 5:171,750,937...171,754,993

G

taste receptor, type 2, member 118

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R118 mRNA

NCBI chr 4:52,449,208...52,450,107
Ensembl chr 4:53,414,815...53,415,714

G

taste receptor, type 2, member 137

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TAS2R137 mRNA

NCBI chr 4:69,279,276...69,286,935
Ensembl chr 4:70,251,091...70,252,041

G

taste receptor, type 2, member 145

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TAS2R131 mRNA

NCBI chr 4:166,138,007...166,138,957
Ensembl chr 4:167,869,358...167,870,544

G

thromboxane A synthase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TBXAS1 mRNA

NCBI chr 4:67,664,963...67,837,096
Ensembl chr 4:68,631,838...68,803,969

G

titin-cap

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TCAP mRNA

NCBI chr10:83,381,719...83,382,887
Ensembl chr10:83,876,939...83,879,483

G

transcription factor 7

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of TCF7 mRNA]

NCBI chr10:36,924,363...36,954,279
Ensembl chr10:36,924,363...36,954,279

G

transferrin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRF mRNA

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:112,647,642...112,695,400

G

transforming growth factor, beta 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TGFB1 protein]

NCBI chr 1:90,324,312...90,340,627
Ensembl chr 1:90,324,046...90,340,899

G

transforming growth factor, beta 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TGFB3 mRNA

NCBI chr 6:111,435,170...111,457,646
Ensembl chr 6:111,435,170...111,456,946

G

thrombomodulin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBD mRNA

NCBI chr 3:156,316,526...156,320,178
Ensembl chr 3:156,306,632...156,320,582

G

thrombospondin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS1 mRNA

NCBI chr 3:125,510,250...125,525,402
Ensembl chr 3:125,510,250...125,525,402

G

thrombospondin 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of THBS4 mRNA

NCBI chr 2:25,718,219...25,760,345
Ensembl chr 2:25,718,219...25,761,369

G

TIMP metallopeptidase inhibitor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP1 mRNA

NCBI chr X:3,766,509...3,772,578
Ensembl chr X:3,766,510...3,771,135

G

TIMP metallopeptidase inhibitor 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP2 mRNA

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:104,041,604...104,089,214

G

TIMP metallopeptidase inhibitor 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TIMP3 mRNA

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:19,409,631...19,459,547

G

thymidine kinase 1

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA; alfacalcidol inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TK1 mRNA]

NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,533,449...103,556,228

G

tolloid-like 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLL1 mRNA

NCBI chr16:25,509,146...25,710,330
Ensembl chr16:30,275,492...30,475,886

G

talin 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLN1 mRNA

NCBI chr 5:57,787,670...57,817,900
Ensembl chr 5:62,583,731...62,613,687

G

toll-like receptor 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR4 mRNA

NCBI chr 5:85,161,247...85,174,882
Ensembl chr 5:85,161,192...85,175,007

G

toll-like receptor 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TLR7 mRNA

NCBI chr X:27,027,380...27,054,309
Ensembl chr X:30,644,355...30,672,151

G

tumor necrosis factor

increases expression
multiple interactions

EXP
ISO

Azoxymethane results in increased expression of TNF mRNA; Azoxymethane results in increased expression of TNF protein
[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA; [Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; isoliquiritigenin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNF protein]; Ursodeoxycholic Acid inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF mRNA]
[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein; Aspirin inhibits the reaction [Azoxymethane results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNF protein]; pinostrobin inhibits the reaction [Azoxymethane results in increased expression of TNF protein]

PMID:17438113 PMID:19028472 PMID:20043115 PMID:20431929 PMID:25026504 More...

NCBI chr20:3,626,685...3,629,303
Ensembl chr20:3,626,532...3,629,303

G

TNF receptor superfamily member 10b

multiple interactions
increases expression

EXP

Aspirin inhibits the reaction [Azoxymethane results in increased expression of TNFRSF10B mRNA]

NCBI chr15:51,249,883...51,278,091
Ensembl chr15:51,250,112...51,278,082

G

TNF receptor superfamily member 11A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFRSF11A mRNA

NCBI chr13:22,442,930...22,501,257
Ensembl chr13:22,442,665...22,501,257

G

TNF receptor superfamily member 12A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:13,211,673...13,213,704

G

TNF receptor superfamily member 18

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF18 mRNA

NCBI chr 5:166,618,461...166,622,353
Ensembl chr 5:171,901,717...171,904,576

G

TNF receptor superfamily member 1A

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFRSF1A mRNA

NCBI chr 4:159,837,119...159,849,817
Ensembl chr 4:159,837,032...159,849,816

G

TNF superfamily member 10

increases expression
multiple interactions

EXP

Azoxymethane results in increased expression of TNFSF10 mRNA
Aspirin inhibits the reaction [Azoxymethane results in increased expression of TNFSF10 mRNA]

NCBI chr 2:112,136,550...112,155,903

G

TNF superfamily member 12

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF12 mRNA

NCBI chr10:54,403,870...54,413,213
Ensembl chr10:54,902,616...54,911,913

G

TNF superfamily member 14

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF14 mRNA

NCBI chr 9:2,068,295...2,073,128
Ensembl chr 9:2,155,270...2,160,191

G

TNF superfamily member 15

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNFSF15 mRNA

NCBI chr 5:77,134,885...77,156,171
Ensembl chr 5:82,150,376...82,171,882

G

TNF superfamily member 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNFSF9 mRNA

NCBI chr 9:2,031,011...2,033,345
Ensembl chr 9:2,030,953...2,033,339

G

troponin C1, slow skeletal and cardiac type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC1 mRNA

NCBI chr16:6,400,801...6,405,634
Ensembl chr16:6,408,607...6,412,070

G

troponin C2, fast skeletal type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNC2 mRNA

NCBI chr 3:153,513,272...153,516,033
Ensembl chr 3:173,932,611...173,935,339

G

troponin I1, slow skeletal type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TNNI1 mRNA

NCBI chr13:47,229,217...47,241,640
Ensembl chr13:49,780,951...49,793,390

G

troponin I2, fast skeletal type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNI2 mRNA

NCBI chr 1:197,595,012...197,597,554
Ensembl chr 1:207,024,416...207,027,038

G

troponin T3, fast skeletal type

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TNNT3 mRNA

NCBI chr 1:197,652,535...197,669,736
Ensembl chr 1:207,081,812...207,099,423

G

tumor protein p53

increases expression
increases phosphorylation

EXP

Azoxymethane results in increased expression of TRP53 mRNA
Azoxymethane results in increased phosphorylation of TP53 protein

PMID:18239060 PMID:20043115

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

two pore segment channel 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPCN1 mRNA

NCBI chr12:35,972,813...36,029,632
Ensembl chr12:41,633,398...41,690,200

G

thiopurine S-methyltransferase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TPMT mRNA

NCBI chr17:17,850,308...17,868,976
Ensembl chr17:17,850,279...17,868,976

G

tryptase beta 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TPSB2 mRNA

NCBI chr10:14,381,779...14,383,571
Ensembl chr10:14,886,360...14,888,100

G

thyrotropin releasing hormone

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRH mRNA

NCBI chr 4:126,299,236...126,301,762
Ensembl chr 4:126,299,236...126,301,762

G

tripartite motif-containing 25

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRIM25 mRNA

NCBI chr10:73,812,818...73,831,271
Ensembl chr10:74,310,022...74,331,716

G

transient receptor potential cation channel, subfamily C, member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC3 mRNA

NCBI chr 2:119,481,313...119,619,333
Ensembl chr 2:121,409,436...121,475,823

G

transient receptor potential cation channel, subfamily C, member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPC6 mRNA

NCBI chr 8:5,759,387...5,864,000
Ensembl chr 8:14,043,877...14,149,304

G

transient receptor potential cation channel, subfamily C, member 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPC7 mRNA

NCBI chr17:7,708,911...7,833,435
Ensembl chr17:7,714,505...7,838,745

G

transient receptor potential cation channel, subfamily M, member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] affects the expression of TRPM1 mRNA

NCBI chr 1:117,718,896...117,835,434
Ensembl chr 1:127,130,686...127,247,391

G

transient receptor potential cation channel, subfamily M, member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM4 mRNA

NCBI chr 1:104,918,462...104,949,453
Ensembl chr 1:104,918,462...104,948,653

G

transient receptor potential cation channel, subfamily M, member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TRPM6 mRNA

NCBI chr 1:225,559,528...225,747,106
Ensembl chr 1:225,576,872...225,747,108

G

transient receptor potential cation channel, subfamily V, member 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV1 mRNA

NCBI chr10:58,349,936...58,375,021
Ensembl chr10:58,340,223...58,375,021

G

transient receptor potential cation channel, subfamily V, member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV2 mRNA

NCBI chr10:47,265,524...47,294,263
Ensembl chr10:47,764,839...47,793,533

G

transient receptor potential cation channel, subfamily V, member 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV4 mRNA

NCBI chr12:47,599,161...47,638,143
Ensembl chr12:47,599,035...47,638,143

G

transient receptor potential cation channel, subfamily V, member 6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRPV6 mRNA

NCBI chr 4:70,507,347...70,523,013
Ensembl chr 4:71,474,007...71,489,671

G

trypsin 5

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TRY5 mRNA

NCBI chr 4:70,213,760...70,217,034

G

TSC22 domain family, member 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TSC22D3 mRNA

NCBI chr X:109,006,410...109,066,389
Ensembl chr X:109,006,420...109,015,519

G

titin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTN mRNA

NCBI chr 3:82,059,648...82,332,130
Ensembl chr 3:82,059,648...82,332,171

G

transthyretin

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of TTR mRNA

NCBI chr18:11,941,791...11,951,008
Ensembl chr18:12,216,732...12,225,969

G

thymidylate synthetase

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of TYMS mRNA

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

ubiquitin-like modifier activating enzyme 7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UBA7 mRNA

NCBI chr 8:108,665,289...108,674,097
Ensembl chr 8:117,543,957...117,556,142

G

uridine-cytidine kinase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of UCK2 mRNA

NCBI chr13:79,380,807...79,438,121
Ensembl chr13:81,916,818...81,971,091

G

UDP-glucose 6-dehydrogenase

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGDH mRNA

NCBI chr14:43,202,480...43,226,002
Ensembl chr14:43,202,356...43,226,629

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT1A6B mRNA

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 2 member A1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2A1 mRNA

NCBI chr14:20,521,018...20,545,934
Ensembl chr14:20,800,263...20,825,111

G

UDP glucuronosyltransferase family 2 member B7

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UGT2B34 mRNA

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:21,251,535...21,274,451

G

unc-80 homolog, NALCN channel complex subunit

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UNC80 mRNA

NCBI chr 9:68,011,940...68,190,135
Ensembl chr 9:75,461,599...75,639,842

G

beta-ureidopropionase 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPB1 mRNA

NCBI chr20:13,217,252...13,243,590
Ensembl chr20:13,216,691...13,277,562

G

uridine phosphorylase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of UPP2 mRNA

NCBI chr 3:43,273,048...43,317,417
Ensembl chr 3:63,681,826...63,726,191

G

vav guanine nucleotide exchange factor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV1 mRNA

NCBI chr 9:2,248,856...2,295,905
Ensembl chr 9:2,248,914...2,296,922

G

vav guanine nucleotide exchange factor 3

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VAV3 mRNA

NCBI chr 2:199,699,861...200,042,344
Ensembl chr 2:199,700,445...200,042,343

G

vascular cell adhesion molecule 1

multiple interactions

EXP

[Plant Extracts co-treated with Azoxymethane] results in decreased expression of VCAM1 mRNA; [Plant Extracts co-treated with Azoxymethane] results in decreased expression of VCAM1 protein

NCBI chr 2:206,723,050...206,742,783
Ensembl chr 2:206,723,044...206,742,801

G

versican

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VCAN mRNA

NCBI chr 2:20,761,718...20,860,637
Ensembl chr 2:22,497,035...22,595,955

G

vitamin D receptor

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VDR mRNA

NCBI chr 7:130,864,764...130,916,757
Ensembl chr 7:130,866,745...130,916,757

G

vascular endothelial growth factor A

multiple interactions
affects expression

EXP

[Linoleic Acid co-treated with Glucose] affects the reaction [Azoxymethane affects the expression of VEGFA protein]

NCBI chr 9:22,452,854...22,468,194
Ensembl chr 9:22,439,392...22,468,194

G

vascular endothelial growth factor C

multiple interactions

EXP
ISO

[2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine co-treated with Azoxymethane] results in increased expression of VEGFC mRNA
[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFC mRNA

PMID:18424890 PMID:29950665

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:44,445,293...44,560,887

G

vascular endothelial growth factor D

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VEGFD mRNA

NCBI chr X:30,073,122...30,108,413
Ensembl chr X:33,706,055...33,740,167

G

vimentin

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIM protein; [titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of VIM mRNA

PMID:29950665 PMID:34273909

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

vasoactive intestinal peptide receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of VIPR1 mRNA

NCBI chr 8:121,303,739...121,339,587
Ensembl chr 8:130,187,731...130,217,096

G

Wnt inhibitory factor 1

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WIF1 mRNA]

NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:58,384,643...58,503,852

G

WNK lysine deficient protein kinase 4

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNK4 mRNA

NCBI chr10:86,202,552...86,219,655
Ensembl chr10:86,702,865...86,720,198

G

Wnt family member 10A

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT10A mRNA]

NCBI chr 9:83,798,594...83,811,060
Ensembl chr 9:83,798,594...83,811,067

G

Wnt family member 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of WNT2 mRNA

NCBI chr 4:46,328,408...46,374,673
Ensembl chr 4:47,294,300...47,421,976

G

Wnt family member 2B

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of WNT2B mRNA

NCBI chr 2:195,142,573...195,156,945
Ensembl chr 2:195,135,176...195,157,144

G

Wnt family member 3

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT3 mRNA]

NCBI chr10:89,180,224...89,224,195
Ensembl chr10:89,216,801...89,224,195

G

Wnt family member 6

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT6 mRNA]

NCBI chr 9:76,329,882...76,343,523
Ensembl chr 9:83,778,552...83,792,186

G

Wnt family member 7B

multiple interactions

ISO

[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA; celastrol inhibits the reaction [[Dextran Sulfate co-treated with Azoxymethane] results in increased expression of WNT7B mRNA]

NCBI chr 7:118,514,684...118,559,316
Ensembl chr 7:118,514,684...118,559,316

G

X-C motif chemokine ligand 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCL1 mRNA

NCBI chr13:79,781,784...79,785,440
Ensembl chr13:79,781,784...79,785,440

G

X-C motif chemokine receptor 1

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XCR1 mRNA

NCBI chr 8:123,479,454...123,516,168
Ensembl chr 8:132,357,020...132,385,862

G

X-linked inhibitor of apoptosis

multiple interactions

ISO

[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein; Aspirin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Camptothecin inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]; Plant Extracts inhibits the reaction [[Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XIAP protein]

NCBI chr X:125,756,107...125,803,979
Ensembl chr X:125,737,971...125,803,978

G

X-prolyl aminopeptidase 2

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of XPNPEP2 mRNA

NCBI chr X:132,165,696...132,194,937
Ensembl chr X:132,165,701...132,195,126

G

zinc finger FYVE-type containing 9

multiple interactions

ISO

[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in increased expression of ZFYVE9 mRNA

NCBI chr 5:123,370,677...123,529,699
Ensembl chr 5:128,599,379...128,758,394

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20862
chemical entity	20860
atom	20860
nonmetal atom	20766
carbon atom	20710
organic molecular entity	20710
Azoxymethane	1069
Path 2
Term	Annotations
CHEBI ontology	20862
subatomic particle	20860
composite particle	20860
hadron	20860
baryon	20860
nucleon	20860
atomic nucleus	20860
atom	20860
main group element atom	20781
p-block element atom	20781
carbon group element atom	20715
carbon atom	20710
organic molecular entity	20710
Azoxymethane	1069

paths to the root